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Background: Proton therapy has an increased dose-conformity compared to 
conventional radiotherapy with photons, and paediatric cancer patients receiving 
cranio-spinal irradiation (CSI) are routinely referred to this treatment modality. With 
long life-expectancy and enhanced radiosensitivity, children are at a significant risk of 
developing radiation-induced secondary cancers, emphasising the importance of 
secondary cancer risk estimations following proton therapy for these patients. Previous 
comparative studies on secondary cancer risk following proton and photon CSI 
treatment plans for paediatric cancer patients have based the proton risk estimates on a 
constant proton relative biological effectiveness (RBE) of 1.1. As the proton RBE 
varies with factors such as linear energy transfer (LET), dose, and tissue type, it is 
important to investigate how a variable proton RBE may affect the secondary cancer 
risk estimates for this patient group. 
Materials and methods: Proton CSI treatment plans for ten paediatric 
medulloblastoma patients were analysed with respect to the risk of radiation-induced 
secondary cancer of the lungs and thyroid by comparing risks predicted by the clinical 
proton RBE of 1.1 to the risk predictions of four variable RBE models (LET-weighted 
dose, the McNamara model, the Rørvik model, and the Wilkens model). By applying 
the organ equivalent dose (OED) concept to different dose-response scenarios, the 
lifetime attributable risk (LAR) and the excess absolute risk (EAR) were estimated 
based on age-, sex-, and site-specific risk coefficients gathered from epidemiological 
data on the Japanese A-bomb survivors.  
Results: All secondary cancer risk estimates were higher for the variable RBE models 
compared to the constant RBE of 1.1 for both organ sites, independent of dose-response 
relationship used. The risk predictions were highest with the variable RBE models that 
used tissue parameters corresponding to late reacting tissues which, depending on 
chosen organ site and dose-response relationship applied, predicted a 9 to 47% increase 
in risk from the constant RBE estimates. 
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Conclusion: Regardless of risk model applied, the estimated risk of radiation-induced 
secondary cancer of the lungs and thyroid will increase when the proton RBE is 
variable and not constant. However, the enhanced secondary cancer risk estimates 
found in this thesis were not high enough to impact the conclusion made by previous 
studies: that proton CSI is the better option compared to photon CSI with respect to 
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Cancer is the second most important cause of death on a global scale, estimated to 
account for 9.6 million deaths in 2018 [1]. In Norway, over 32 000 new incidences of 
cancer were reported in 2016 where the cancer incidence has shown a persistent 
increase over the past 50 years for all cancer sites [2]. The same trend is shown for 
cancer survival, reflecting the improvements in both early detection and treatment of 
cancer.  
Radiotherapy is one of the leading modalities used for cancer treatment in developed 
countries, with more than half of cancer patients receiving radiotherapy either alone or 
in combination with other modalities, mainly surgery and chemotherapy [3]. In 
radiotherapy, the dose delivered to the tumour to kill the cancerous cells is in the form 
of energy deposited by ionising radiation, aiming to deliver high radiation doses to the 
tumour volume while sparing the surrounding normal (healthy) tissue by keeping the 
dose here minimal [4]. 
1.1 Radiotherapy – past and present 
The discovery of x-rays by the German physicist Wilhelm Conrad Röntgen in 1895 is 
considered the starting point of radiotherapy, which has been used in cancer treatment 
for more than a century [5]. Within the three following years, Antoine-Henri Bequerel 
and Pierre and Marie Curie discovered radioactivity emitted by radioactive sources, 
and a few years later radium was employed in cancer treatment. Both Bequerel and 
Pierre Curie recorded the biological effects of radiation they experienced through 
accidental (by Bequerel) and intentional (by Curie, allegedly) skin contact with 
radioactive sources, thus giving an introduction to the study of the action of radiation 
on living material, called radiobiology [5]. 
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Since the early 1900s, radiotherapy has been undergoing massive improvements, 
including the invention of the CT scan by Hounsfield in 1971 that introduced 
computers in treatment planning, shifting it from 2D to 3D planning, and the use of 
multileaf collimators for 3D dose sculpting [6]. These inventions gave rise to the 3D 
conformal radiotherapy (3D-CRT). The early 2000s took this further by modulating 
the photon beam intensity during delivery, using so-called intensity-modulated 
radiotherapy (IMRT).  
Treatment modalities using photons (e.g. 3D-CRT and IMRT) and electrons are the 
most common in radiotherapy today, with radiotherapy using protons as a promising 
alternative due to the possibility of reducing the dose to healthy tissues whilst avoiding 
a decline in the total dose to the tumour volume [4]. 
1.2 Proton therapy 
Protons were first suggested as a possible candidate for particle therapy (radiotherapy 
with hadrons) in 1946 by Robert R. Wilson [7]. This suggestion was based on the 
spatial distribution of the proton energy deposition when traversing through material 
which differ from photons in that the main part of the energy is deposited at the end of 
the proton beam range, giving rise to what is called the Bragg peak (Figure 1.1) [4, 8]. 
Despite the promises this energy distribution could hold for conforming dose to the 
tumour and reduction of healthy tissue dose, proton therapy for treatment of cancer in 
humans was only used in moderate cases before experiencing an increase in use from 
the late 1980s and early 1990s [4]. Today, there are currently 71 proton therapy centres 
in operation around the world, and out of the more than 175 000 patients treated with 
particle therapy in 2016, about 145 000 received proton therapy [9, 10].  
The physical properties of protons are well understood, but there still exist uncertainties 
regarding how protons affect biological matter. Proton radiation, like other ionising 
radiation, induce cell killing which makes it efficient at terminating cancerous cells 
when used as a modality in cancer treatment. Despite having an improved dose-
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conformity over other radiotherapy modalities, protons can still irradiate normal 
tissues. Proton dose deposition in normal tissues can cause a number of serious acute 
and/or late side effects, which in rare cases includes the manifestation cancer.  
Radiation-induced cancer is called a long-term or late effect due to the often long 
latency period between radiation exposure and manifestation of disease [11]. Unlike 
photons, which have an extended history of use in clinical practice and thereby more 
experience with possible tissue effects, less is known about proton biological effects. 
In clinical practice today, protons are assumed 10% more biologically effective than 
photons, based on results from experiments on cells and animals [12, 13]. How 
biologically effective one type of radiation is compared to a reference radiation, is 
termed relative biological effectiveness (RBE), and for protons compared to photons 
(reference radiation) a constant RBE of 1.1 is used clinically. As it has been established 
that the RBE value of protons depends on many factors, this is a simplification and the 
proton RBE can potentially deviate appreciably from the value of 1.1, especially in the 
distal parts of the proton Bragg curve [13]. Thus, variable RBE models have been 
developed to account for variations in the proton RBE based on factors such as linear 





Figure 1.1: Illustration of depth dose depositions of protons (solid blue line) 
and photons (solid red line) traversing through tissue, with the dashed blue 
line representing the combination of multiple proton beams, forming a so-
call spread-out Bragg peak (SOBP) [14]. 
1.3 Secondary cancer risk 
Over the past several decades, the constant improvements in radiotherapy regarding 
tumour control and healthy tissue sparing has led to a significant increase in cancer 
cure rates and life-expectancy after treatment among cancer survivors [15]. Many 
countries also experience an age increase in the population and thereby a rise in the 
probability of cancer development, resulting in more cancer to be considered for 
radiation treatment. When ionising radiation has been used to successfully treat a 
primary tumour in a patient, the radiation may have caused sufficient amounts of cell 
damage and mutations in surrounding healthy tissue to increase the risk of inducing a 
new, or secondary, cancer [16]. The risk of developing a secondary cancer persists 
throughout life for radiotherapy survivors and, as most secondary cancers have a long 
latency period, increases with prolonged life after radiation treatment. This enhances 
the importance of using predictive modelling to estimate the potential increase in 
radiation-induced secondary cancer risk when evaluating different treatment options 
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for each patient case [15, 17]. Generally, information gathered from epidemiological1 
studies on irradiated populations and cancer registries from earlier radiotherapy is used 
as a basis for such secondary cancer risk models [18]. 
Children have a long life-expectancy after treatment, and thereby an enhanced risk of 
secondary cancer incidence. Children are also more radiosensitive than adults [15], 
further elevating the risk of developing a radiation-induced secondary cancer among 
paediatric cancer patients. Due to the improved dose-conformity of proton therapy 
compared to other radiotherapy techniques, this modality is routinely considered for 
the treatment of paediatric cancer patients [4]. Because there currently is no available 
epidemiological data or secondary cancer registries following proton therapy, 
predictive modelling of radiation-induced secondary cancer risks following proton 
therapy treatment is of particular importance to these patients. 
1.4 Project objectives 
For paediatric cancer patients, the most common malignant brain tumour is 
medulloblastoma [19]. In addition to surgery and chemotherapy, paediatric 
medulloblastoma is treated with cranio-spinal irradiation (CSI), with 5-year survival 
rates in the order of 80% [20]. Paediatric medulloblastoma patients receiving radiation 
treatment for their disease are at a significant risk of developing radiation-induced 
secondary cancers after treatment [21-23]. The promise of increased dose-conformity 
with proton therapy compared to photon therapy has caused many studies to compare 
proton CSI with photon CSI with respects to secondary cancer risk estimates following 
these treatment modalities for paediatric medulloblastoma patients [24-31]. All studies 
used a generic proton RBE of 1.1 for the proton CSI plans, which had the overall best 
results regarding possible secondary cancer risk compared to the photon CSI plans in 
                                              
1 Epidemiology is the study of the distribution of disease and disease-related factors in the human population 
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every study, without exceptions. It is therefore of interest to investigate how a variable 
proton RBE may affect the risk estimates for this patient group. 
The main objective of this thesis was to estimate the risk of radiation-induced 
secondary cancer of specific sites following proton CSI treatment with both constant 
and variable RBE for paediatric medulloblastoma patients, to investigate whether the 
variations in RBE would result in a different risk compared to the constant RBE of 1.1. 
The calculations included four variable RBE models in addition to the constant RBE, 
which all were combined with different dose-response scenarios to estimate risk of 




2. Physics of proton therapy 
During radiotherapy, energy is transferred to the tissue as a result of the interaction 
between the beam particles and the traversed material [32]. Radiation is termed ionising 
radiation if the beam particles have sufficient energy to free electrons completely from 
the atoms or molecules in the material, i.e. to cause ionisation. Direct ionisation is 
possible for charged particles (electrons, protons, heavier ions) with enough energy to 
cause an interaction between the electromagnetic fields of the charged particle and the 
atomic electrons or nuclei (i.e. electromagnetic interaction), whereas photons and 
neutrons are termed indirectly ionising as they must first interact with the material to 
liberate directly ionising particles [32]. This chapter summarises the basic interactions 
of proton therapy – the interactions of the primary charged particles, i.e. the protons, 
and the interactions of the secondary uncharged particles that can be produced during 
proton therapy beam delivery, i.e. photons and neutrons. 
2.1 Charged particle interactions with matter 
Heavy charged particles interact with matter primarily in three ways: slowed down by 
electromagnetic (or Coulomb) interactions with atomic electrons, deflected by 
electromagnetic interactions with atomic nuclei or undergo nuclear interactions with a 
nucleus [4]. Protons fall into the category of “heavy” charged particles, which include 
all charged particles with a large rest mass compared to the rest mass of an electron 
[33].  
2.1.1 Stopping power 
The main energy loss of heavy charged particles is through electromagnetic 
interactions with atomic electrons, resulting in ionisation or excitation (i.e. raising the 
electron to a higher electron shell) of the atom [32, 34]. These electromagnetic 
interactions are referred to as inelastic collisions and they cause the charged particles 
to gradually slow down and eventually come to a complete stop. The rate of energy 
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loss per unit path length (dE/dx) is called the stopping power [4]. For the initial beam 
energies for proton therapy of typically up to 220 MeV/u, the rate of energy loss 
dominated by these inelastic collisions can be described by the Bethe-Bloch formula 
(given in the relativistic version by Fano (1963) [35]) [36]: 
Here, Zp and Zt are the charge of the projectile (particle) and the target, me and e are the 
electron mass and charge, 〈𝐼〉 is the mean ionisation energy of the target atom or 
molecule, β is the particle velocity, v, relative to the speed of light, C/Zt is the shell 
correction and δ/2 is the density effect correction [36].  
The stopping power is inversely proportional to the proton velocity which causes the 
energy loss to increase as the proton slows down, resulting in a maximum energy 
deposition at the end of the particle track (end-of-range), called the Bragg peak (Figure 
1.1) [4, 8]. The range is defined as the depth at which half of the particles in the material 
have come to rest [37]. As the protons in a monoenergetic beam will experience 
individual interactions, they will not all stop at the same depth in the material [4]. This 
is called range straggling and is what defines the width of the proton Bragg peak [37]. 
2.1.2 Deflection and nuclear interaction 
As protons are much heavier than electrons, the interactions with atomic electrons have 
little effect on the proton trajectory [34]. However, when protons undergo 
electromagnetic interactions with atomic nuclei, the protons are scattered, resulting in 
small deflections of the proton trajectories [4]. The sum of all these deflections can 
cause a significant lateral spread of the proton beam [34]. 
Although far less likely compared to the electromagnetic interactions, protons may also 
undergo nonelastic nuclear interactions by head-on collisions with a nucleus [4, 34]. In 






















some of the proton energy which can cause an emission of secondary particles, such as 
protons and neutrons, that can travel relatively large distances and further increase the 
energy deposition in the material [34, 37]. 
2.1.3 Linear energy transfer 
The ionisation density of protons varies with the proton energy, and thus with the 
position/depth in the patient.  The ionisation density is related to the rate of energy loss 
per unit path length along the proton track, known as the linear energy transfer (LET) 
(Figure 2.1), which is inversely proportional with the proton energy and therefore 
increases with depth, in particular near the Bragg peak [38]. The LET ranges from 0.39 
keV/µm for 250 MeV protons (highest therapeutically used energy for protons), rising 
with decreasing energy and reaching a maximum of 83 keV/µm at proton energies of 
0.08 MeV [39]. The high-LET values in the Bragg peak region are related to an 
enhanced biological effectiveness when it comes to cell killing and may result in more 
severe biological damage than e.g. photon radiation (more on this in chapter 3). 
In 1952, Zirkle et al. defined the LET as the average energy, dEΔ, transferred to the 
material from a charged particle traversing the distance, dl [40, 41]: 
LΔ, usually expressed in units of keV/µm, refers to the restricted LET which excludes 
the energy carried away by secondary (i.e. freed) electrons with energies greater than 
Δ, i.e. with an energy cutoff of Δ [41]. When no energy cutoff is enforced, the 
unrestricted LET is equal to the stopping power, often denoted L∞ or simply L. 
In most experimental situations, there is a range of LET values, which the definitions 
above are unable to account for as they only apply to single particles or monoenergetic 
beams [42]. Therefore, the mean LET value is often reported, either as the track-







LETd is the most common to use in proton therapy and in modelling the biological 
effects of protons (chapter 3.3.1). LETd is the mean value of the individual proton 
LETs, each weighted by the dose it deposits [42]. It accounts for both dose and LET, 
which is important when considering the biological outcome of radiotherapy [43].  
 
Figure 2.1: LET as a function of proton beam energy through 
water [13]. 
2.2 Photon interactions 
Photons (x-rays and γ-rays) passing through matter may interact with the atoms of the 
traversing material – through interactions involving either the atomic electrons or the 
atomic nucleus – resulting in the photon being either completely absorbed or scattered 
[32, 44]. The number of photons that undergo such interactions is proportional to the 
number of incident photons and the thickness of the traversing material, and for a 
monoenergetic photon beam can be expressed as the decrease of photon beam intensity, 
I(x), in the material of thickness x: 




where I0 is the initial photon beam intensity and µ is the linear attenuation coefficient 
that yields the probability of photon absorption or scattering per unit path length [32, 
45].  
There are three principal processes of photon interaction which cause the attenuation 
of a photon beam in matter: photoelectric absorption, Compton scattering and pair 
production [32]. In photoelectric absorption, the photon is completely absorbed by the 
atom resulting in the ejection of one of the orbital electrons. In Compton scattering, the 
photon collides with a “free” atomic electron (atomic electron with binding energy 
much less than the incident photon energy), ejecting the electron from the atom and 
scatters with reduced energy [32]. For energies exceeding 1.022 MeV (the energy 
equivalent of the mass of an electron/positron pair) pair production may also occur, i.e. 
a photon is absorbed in the vicinity of an atomic nucleus and an electron/positron pair 
is created [45, 46].  
2.3 Neutron interactions 
Neutrons interact with atomic nuclei through three principal processes: elastic 
scattering, inelastic scattering and neutron capture [46]. The scattering processes 
(where inelastic scattering dominates at neutron energies above 10 MeV, and elastic 
scattering dominates at lower energies) cause the neutrons to slow down until they 
reach thermal energies and are completely absorbed (i.e. captured) by the nuclei and 
replaced by secondary radiations [4, 45, 46]. Secondary protons can also be produced 
by elastic scattering of fast neutrons with hydrogen nuclei, and the deposition of kinetic 
energies attained from the collision will contribute to the total energy deposition in the 




2.4 Dosimetry and depth dose curves 
2.4.1 Absorbed dose 
The radiation energy that is absorbed by matter is referred to as radiation absorbed 
dose. The absorbed dose is the basic physical dose quantity used for reporting dose in 
clinical radiotherapy as well as in radiological protection and radiation biology [47]. 
The absorbed dose, D, is defined as the mean energy, 𝑑 ,̅ imparted to a unit mass, dm, 
by ionising radiation [41]: 
in SI units of J/kg, with special unit name gray (Gy). This definition applies to all types 
of ionising radiation of all energies traversing through a material [32]. The absorbed 
dose only gives information regarding the energy deposition of a particle and must 
therefore be modified by additional factors to account for different biological effects 
of each specific radiation type as well as the type of irradiated biological material/tissue 
[47]. For radiation protection purposes regarding low-dose exposure, the average 
absorbed dose in a tissue or an organ (T) is weighted by a radiation weighting factor 
wR with respect to the biological effect of the radiation (R), called the equivalent dose, 
the sum of which can further be weighted by a tissue weighting factor wT to account 
for the sensitivity of the exposed tissue or organ, called the effective dose [47]. Both 
terms are expressed in units of J/kg, with special unit name Sievert (Sv). For the high-
dose exposures of particle therapy, different modifications to the absorbed dose are 
recommended (explained in chapter 3) [48]. 
2.4.2 Dose deposition and the Spread-out Bragg peak 
An illustration of the depth dose curves of protons and photons is given in Figure 1.1, 
showing that the proton deposits less energy traversing through matter compared to the 







i.e. the Bragg peak. The photon depth dose curve, on the other hand, has a maximum 
energy deposition near the entrance of the material, or tissue, decreasing exponentially 
with depth (in accordance with eq. (2.3)) [49]. The goal for proton therapy is to have 
the Bragg peak positioned inside the target volume, i.e. the tumour. To ensure that the 
entire target volume is receiving the prescribed proton dose, the combination of many 
different mono-energetic proton beams is used in the treatment delivery, forming what 
is called a spread-out Bragg peak (SOBP), also illustrated in Figure 1.1 [4]. This SOBP 
can be achieved by what is called passive scattering (PS); using filters adapted to the 
patient and target volume, adjusting the proton beam to spread laterally to fit the target 
and to give a uniform dose distribution in the depth direction [4]. It can also be done 
by delivering the proton beam into the patient with less filters, steering the beam 
laterally with the help of e.g. magnetic fields and adjusting the beam energy to deliver 
the beam in different depths of the target volume. This is called pencil beam scanning, 




3. Radiobiology of protons 
Radiobiology is the study of how ionising radiation interacts with living matter [5]. It 
is well-established that ionising radiation is a carcinogen, i.e. it promotes the formation 
of cancer as a result of changes in the molecular structures caused by radiation damage 
to the cells [18]. The initial phase of radiobiological cell damage is set in motion by the 
physical process of interactions between ionising radiation and the atoms or molecules 
within a cell [16]. All subsequent processes (i.e. biological effects) are included in the 
biological phase. This includes how damage to the DNA of the cell can cause cell death 
or genetic mutations that may lead to cancer induction (carcinogenesis) [11].  
3.1 The radiobiological impact of ionising radiation 
The critical target in a cell is the DNA and damage to the DNA causes most biological 
effects of ionising radiation [5]. This includes cell killing, DNA mutations and 
carcinogenesis. There are two ways for ionising radiation to interact with biological 
matter [5]. The first is by ionising or exciting the target atoms, called direct action (the 
most common interaction for high-LET radiations), which starts the process that leads 
to biological alterations. The second is by interaction with other cellular atoms or 
molecules, called indirect action (which is around two thirds of the biological damage 
from photon radiation), generating highly reactive molecules that can cause damage to 
the DNA.  
The most common radiation-produced lesions of DNA damage are single-strand breaks 
(SSB) and double-strand breaks (DSB) [49]. With DSB, both strands of the DNA helix 
are severed, making it impossible for one strand to act as a template for the repair of 
the broken strand (which is possible for SSB). Thus, DSB can be seen as critical lesions 
that may lead to most of the early and late radiation-induced effects. Several studies 
have proposed that the induction of DSB is higher for protons than for photons at 
clinically relevant energies, especially where protons have higher LET values (i.e. near 
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the Bragg peak) [49]. To assess the effect on cell killing, measurement of surviving 
cells after irradiation is performed in in vitro2 studies [38]. 
The carcinogenic effect is stochastic, meaning that the probability of cancer formation 
is dose dependent, but the severity of the induced cancer itself has no relation to the 
dose [5]. In contrast, deterministic effects, such as radiation-induced skin redness, 
occur above a threshold dose, where the severity of the effect increases with dose [50]. 
Incorrectly repaired damage in a cell may lead to genetic mutation, where such 
mutations in somatic cells could be involved in cancer formation [11].  
Radiation carcinogenesis is a multistage process, occurring over a long time period, 
where the induction of the initial mutation is called the initiation stage [17]. This is 
followed by a promotion phase expressing the acquired mutations. The last stage of the 
carcinogenesis process is the malignant progression phase. Here, the cells attain further 
mutations and thus become invasive. It may take several years, even decades, from 
starting the initiation stage until the clinical manifestation of the disease occurs. 
3.2 The linear-quadratic model 
Cell experiments quantifying cell survival after irradiation have been used to assess 
biological effects of ionising radiation. For instance, the number of surviving tumour 
cells can be used to model the tumour control probability (TCP), and normal tissue cell 
lines can be used to model the normal tissue complication probability (NTCP) [16]. 
The resulting cell survival curves are plotted as the surviving fraction against radiation 
dose, usually on a semi-logarithmic scale (Figure 3.1a) [16]. Radiobiological models 
are often applied to describe and analyse the relationship between cell survival and 
radiation dose in order to relate experimental data to clinical cancer treatment. The 
                                              
2 Experiments and procedures done outside living organisms, e.g. laboratory examinations of tissues and cell cultures done 
in test tubes. This is opposed to in vivo studies – experiments and procedures done inside a living organism 
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linear-quadratic (LQ) model [51] is frequently used to give a mathematical description 
of the continually downward bending shape of the cell survival curve (Figure 3.1b), 
fitting the curve by an exponential second-order polynomial, thus yielding the formulae 
for cell survival as a function of absorbed dose D [16]: 
The ratio of the parameters α and β determines the shape of the curve. To give the LQ 
model a mechanistic justification, an interpretation that the linear component 𝑒−𝛼𝐷 
comes from single-track events and the quadratic component 𝑒−𝛽𝐷
2
 comes from 
double-track events has been proposed [16]. A single-track event is when a single hit 
from a particle track damages a site within a cell, whereas a double-track event is when 
two consecutive particle tracks hit and damage the same site within a cell. The 
quadratic component is therefore dependent on the dose-rate as a higher dose-rate will 
give less time for cell repair between hits. Thus, the α/β ratio gives the deposited 
radiation dose where the linear damage contribution is equal to the quadratic 
contribution, i.e. when 𝛼𝐷 =  𝛽𝐷2 [16].  
The α/β values are dependent on tumour or tissue type, with high α/β ratio for early 
responding tissues and fast growing tumours (expression of damage occurring days to 
weeks after irradiation) and low α/β ratio for late responding tissues and some slow 
growing tumours (expression of damage occurring months to years after irradiation) 
[16, 52]. The α/β ratios of the different tissue- and tumour types are used to describe 
fractionation3 sensitivity and to make decisions regarding fractionation schemes in 
radiotherapy. Although several publications list α and β values obtained from the 
proton radiation survival curves, these are often characterised by large uncertainties, 
                                              
3 Dose fractionation – delivering the total radiation dose is divided into several fractions with lower dose – is a common 
practice in radiotherapy 





and most of the literature therefore primarily use the α/β ratios for the reference x-
ray/photon radiation when referring to cell/tissue type [13]. α/β values obtained from 
photon radiation survival curves will hereby be referred to as (α/β)x, in accordance with 
literature. 
 
Figure 3.1: Cell survival curves, where a) show a typical cell survival curve for cells 
irradiated in tissue culture with low-LET radiation and b) show cell survival curves and 
parameters of the LQ model for both high-LET (straight solid line) and low-LET (bended 
solid line) [16]. 
There are some limitations to the LQ model, due to unclear validity at low doses (< 
approx. 1 Gy) and at high doses (> approx. 10 Gy) [13]. Other cell survival models 
based on the LQ model have been proposed to account for these limitations. 
3.3 Relative biological effectiveness – RBE 
The relative biological effectiveness, or RBE, of protons is a measure of how 
biologically effective proton radiation is compared to a reference radiation (e.g. 60Co 
photons) when applying the same physical dose. The radiation doses should, per 
definition, be given under identical conditions to make the definition of RBE valid.  
The International Commission on Radiological Units and Measurements (ICRU) 
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recommends using the RBE-weighted dose with units Gy(RBE) (i.e. the proton 
absorbed dose, Dp, multiplied with the proton RBE) to represent the corresponding 
dose of photons, Dx, that will produce the same biological effect under the same 
conditions [48]. The proton RBE can therefore be described as the ratio of isoeffective 
absorbed doses of the reference radiation and the proton radiation that generate the 
same biological effect: 
In clinical proton therapy, a generic value for proton RBE of 1.1 is used, meaning that 
proton radiation is assumed 10% more biologically effective than photon radiation for 
the same absorbed dose. This value of 1.1 has been obtained from experimental data as 
an average of measured RBE values, which mainly comes from in vivo studies on 
animal systems in the 1970s [12, 13]. RBE values obtained from in vitro data on the 
endpoint4 of cell survival are typically somewhat higher.  
The proton RBE is dependent on the total dose and dose fractionation, beam quality, 
tissue type and biological endpoint, and may thus vary with these factors. There have 
been several advances in understanding and determining proton RBE values since the 
animal studies in the 1970s, including increased clinical experience, published RBE 
values that deviate from the generic value and new models developed to determine how 
RBE may vary with additional factors. Such advances brings into question whether this 
value should be implemented as a variable and not a constant in treatment planning and 
optimisation [12]. If the proton RBE deviates from the generic value of 1.1, this could 
have clinical implications and impact on the estimation of radiation-induced side 
effects, including secondary cancer risk for proton therapy. To describe this further, 
                                              







one must look at the different RBE dependencies and how these may contribute to 
variations of the proton RBE. 
3.3.1 RBE as a function of LET 
The combination of dose-averaged LET (LETd) and RBE-weighted dose contribute to 
the proton RBE at each point in the SOBP. Figure 3.2 illustrates how LETd distributions 
of a proton beam show a slight increase throughout the SOBP, with a significant 
increase in LETd value, and thus in RBE value, at the distal end of the SOBP [12, 13]. 
This effect becomes greater for proton beams with lower initial energy and smaller 
modulation widths, potentially reaching a maximum LETd value of around 20 keV/µm 
in the fall-off region [13]. In general, the proton RBE has shown an increase with 
increasing LETd and the variable RBE models in Figure 3.2 demonstrate that the proton 
RBE is potentially much larger than 1.1 at LETd values approaching the maximum 







Figure 3.2: Illustration of a proton SOBP depth dose distribution with clinical RBE of 1.1 
(red line) and the respective LETd distribution (blue line). The relationship between RBE 
and LETd is demonstrated by the curves for the two variable RBE models of Wilkens (green 
line) and Wedenberg (yellow line) with corresponding RBE values shown by the RBE scale 
on the far right [53]. 
3.3.2 Other RBE dependencies 
There has been established an RBE dependency on (α/β)x, on dose and dose 
fractionation, and on clinical and biological endpoints. In general, an increase in RBE 
is observed with decreasing (α/β)x [13, 54]. The higher α/β shown in proton 
experiments compared to photon experiments leads to an increase in RBE with 
decreasing dose [54]. Lastly, the clinical proton RBE value of 1.1 is for the endpoint 
of cell inactivation and tumour response, and other clinical and biological endpoints 






3.3.3 RBE models 
There have been several phenomenological models5 proposed to account for possible 
RBE variations as an alternative to using the generic proton RBE of 1.1. Most of these 
models are derived from fits to experimental data points and calculate the proton RBE 
using RBE formalisms based on the LQ model. Using equation (3.2) within the LQ 
framework (eq. (3.1)), RBE can be expressed as a function of the proton dose, Dp, and 
the tissue parameters α and β for protons and αx and βx for photons [13, 56, 57]: 
From this, the RBE in the higher limit of surviving fraction (RBEmax) can be obtained 
when 𝐷𝑝  =  0 [58], and the RBE in the lower limit (RBEmin) can be obtained when 
𝐷𝑝 → ∞ [59]: 
From these two functions, describing the extreme RBE at low and high doses, 
respectively, equation (3.3) can be written as 
                                              
5 Phenomenological models describe the empirical relationships of phenomena observed in experiments without explaining 
the underlying cause of these relationships 








































Equation (3.6) is common for all LQ-based RBE models, whereas the differences 
between these models occur in their definition of RBEmax and RBEmin. Results have 
shown varying degrees of RBE dependence on LETd, either through a linear 
relationship (e.g. McNamara, Wilkens, Wedenberg, Carabe) [39, 60] or a non-linear 
(e.g. Rørvik) [61]. Other models have had a stronger focus on variations in LETd for 
proton therapy plans by using the LETd distribution directly, assuming a linear 
dependency of LETd on RBE (Unkelbach) [62]. Different variable RBE models are 
shown in relation to a constant RBE of 1.1 in Figure 3.3. Here, the model predictions 
of variable proton RBE values could affect risk estimations of radiation-induced 
secondary cancer for proton therapy in a way that may differ from such estimations 
calculated using the clinical value of 1.1. 
 

























Figure 3.3: Depth dose distributions of SOPBs in water calculated by different RBE models 
using an (α/β)x value of 3.76 Gy. The RBE estimates of the different RBE models (in 
colours) are shown in relation to the clinical RBE value of 1.1 (dotted black line), with the 





4. Estimating radiation-induced secondary cancer 
for proton therapy 
Developing a radiation-induced secondary cancer after the successful treatment of a 
primary cancer has been a concern for many years, dating back to the first decades of 
radiotherapy. In the following years, many epidemiological studies have therefore been 
conducted regarding the carcinogenic effect of radiotherapy, and they have shown that 
radiotherapy leads to a small but significant risk of secondary cancer induction [17]. 
Several of these studies have also pointed out different factors that may influence the 
risk of secondary cancer incidence following radiotherapy. These factors include for 
instance genetic susceptibility, hormonal mechanisms, lifestyle and age [11]. The age 
factor underlines that the risk of secondary cancer induction is of particular importance 
to paediatric patients due to their long life expectancy after treatment as well as 
increased radiosensitivity. These patients also have high long term survival rates (the 
5-year relative survival rate for children of 0-14 years from 2005-2011 was 83.4% for 
all childhood cancers [64, 65]) which emphasises the relevance of secondary cancer 
risk for this patient group [27, 29, 66]. Literature investigating the potential benefits of 
proton therapy compared to photon therapy exist for paediatric patients [24-31, 66-68] 
and exhibit indications that proton therapy may be a better option in reducing potential 
side effects, at least for specific cancer sites. To establish whether there truly is an 
advantage in using proton therapy over photon therapy in treatment of paediatric 
cancers, long-term post-treatment follow-up studies are needed. 
Generally, epidemiological studies on radiation aim to describe the different effects of 
ionising radiation in exposed populations [18]. There is little to no data on secondary 
cancer incidence following proton therapy that can be used for risk assessments for this 
modality. Therefore, data from epidemiological studies on (non-proton) radiation 
combined with theoretical modelling can be used to estimate the risk of secondary 
cancer incidence following a successful proton therapy treatment. Epidemiological 
studies directly concerning the carcinogenic effect of radiotherapy are only a fraction 
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of the epidemiological studies on the effects of radiation in exposed populations. Other 
radiation exposed groups can include those subjected to accidental exposure, 
professional exposure, and medical exposure for diagnostic purposes [11]. Due to the 
statistical power of some of these studies (which include large cohorts, thorough 
follow-up, large ranges of radiation doses etc.), they form the basis for many risk 
estimations on secondary cancers following radiotherapy, including risk estimations 
made by the Biological Effects of Ionizing Radiation (BEIR) VII report and the United 
Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) report 
[18, 69]. However, these epidemiological data mostly concerns irradiated populations 
exposed to radiation doses quite different to what is commonly used in radiotherapy 
(e.g. more uniform dose distributions, and whole body irradiation) [11, 70]. 
Furthermore, the radiation techniques from data on the follow up of cancer patients are 
no longer in use and are also quite different from the radiation techniques used today. 
Thus, theoretical models for predicting the risk of radiation-induced secondary cancer 
have been developed to extrapolate such epidemiological data to modern day radiation 
treatment techniques and dose-ranges relevant for radiotherapy as well as using the 
proton RBE to make the doses from e.g. photon irradiation applicable to proton therapy 
[17, 54]. 
4.1 Epidemiological data 
Data from epidemiological studies can be used to quantify the risk of developing a 
radiation-induced cancer as well as to determine the different factors that can affect 
this development. There has also been a focus on finding a relationship between the 
risk of developing certain types of cancer and the average dose relevant for these cancer 
inductions [70]. Epidemiological studies that can be used for cancer risk estimations 
following radiotherapy are presented below. The information about the studies 
presented here are gathered primarily from the BEIR VII report [18] and the 
UNSCEAR report [69] and concern the follow-up of the Japanese A-bomb survivors 
and patients irradiated for medical purposes. Studies on occupational exposure and 
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environmental exposure are not included because of the difficulty in assessing the risk 
of radiation-induced cancers following these types of exposure, either due to lack of 
information regarding the received radiation dose (occupational) or inability to provide 
reliable risk estimates (environmental). 
4.1.1 The Life Span Study cohort 
The follow-up of Japanese survivors of the atomic-bombings of Hiroshima and 
Nagasaki, also referred to as the Life Span Study (LSS) cohort, is deemed the most 
important cohort of irradiated populations studied for the development of cancer risk 
estimates for irradiated populations [5, 18]. This is mainly due to its large population 
size of approx. 120 000 people, where the 93 000 persons who were in one of the cities 
during the bombings have been the primary cohort for analyses since the early 1970s 
[18]. Other factors that make this cohort valuable in radiation epidemiology is the long 
and thorough follow-up, that the cohort consists of persons of both sexes and of all 
ages, and that the cohort received short-term exposure to different doses of high- and 
low-LET radiation [11]. The LSS cohort received doses of γ- and neutron radiation at 
high dose-rates, where around 50 000 of the survivors received doses between 5 mSv 
and 2 Sv [5, 18]. The survivors that were exposed at low doses are often used in 
assessing the biological effects at these dose levels, and the many survivors exposed at 
higher dose levels form a basis for estimating risks that can be related to therapeutic 
irradiations [18]. Despite that there exist uncertainties regarding exact dose received 
by the survivors as well as the pattern of irradiation, the data from this group has formed 
the basis for many radiation-induced secondary cancer risk estimations. Specifically, 
for the doses ranging from around 0.1 Gy to 2.5 Gy, a linear dose-response relationship 
has been produced by the data from this cohort, which is referred to as the “gold 
standard” and viewed as a good estimation for secondary cancer risk following these 




Figure 4.1: Schematic dose-response relationship for radiation-
induced carcinogenesis in humans. The atomic-bomb data 
represents the “gold standard” – the best quantitative data over a 
dose range of approximately 0.1-2.5 Gy. There are considerable 
uncertainties in the dose-response relationship above and below 
this dose range [71]. 
Because the LSS cohort received whole-body irradiations, reports on health risks 
following radiation exposure, like BEIR VII and UNSCEAR, have been able to assess 
risks for specific cancer sites  and evaluate the comparability of these site-specific risks 
[18, 69]. 
4.1.2 Medical exposure 
One of the largest populations that provide epidemiological data on the effects of 
radiation is patients irradiated for medical purposes, either by diagnostic examination 
or through treatment of benign or malignant disease [11, 18]. Patients receiving 
radiation for diagnostic purposes make up the largest subgroup, and are typically 
exposed to low radiation doses of about 0.5 mSv annually, with examinations occurring 
at least twice a year on average [18]. Because of this low dose exposure, the findings 
of studies on diagnostic irradiation regarding risk of cancer induction may be difficult 
to apply to radiotherapy patients receiving much higher doses over a shorter time 
period. Thus, epidemiological data on follow up of cancer patient cohorts that have 
undergone curative radiotherapy have been suggested as the data that can provide the 
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best estimates of radiation-induced secondary cancer risk [11]. The higher doses that 
are delivered to the target volume are typically in the 50-60 Gy dose-range, and the low 
doses that can be received by organs further away from the target area are usually 100 
mGy or less [18]. These studies can therefore provide information on secondary cancer 
risk following both high and low radiation doses as well as the effects of fractionation 
used in radiotherapy and site-specific secondary cancer risk [18, 69]. The effects of cell 
killing and fractionation have been assumed to be largely the reason for the generally 
lower risk estimates following radiotherapy compared to those for the LSS cohort [69]. 
Clinical evidence 
Generally, studies that aim to estimate secondary cancer risk following radiotherapy 
have focused on patients receiving radiation treatment for malignant diseases who have 
a high chance of long-term survival, such as patients with cervical cancer, breast 
cancer, Hodgkin’s disease, and childhood cancers [18]. Studies on the risk of radiation-
induced secondary cancer for cervical cancer patients have provided risk estimates for 
breast cancer, leukaemia, and stomach cancer and have generally shown an increase in 
risks for cancers of the stomach, rectum, urinary bladder, bone and joints [18, 69]. 
Another studied group is patients treated for Hodgkin’s disease, or Hodgkin’s 
lymphoma, which is a special case of lymphoma6 that has mostly been treated with a 
combination of radiotherapy and chemotherapy [18]. A number of cohort and case-
control studies on the treatment of Hodgkin’s disease has been conducted, showing a 
general increase in secondary cancer risks of the lungs and breast [69]. Secondary 
cancer risks following radiation treatment of childhood cancers have been evaluated 
by combining data gathered by different groups world-wide [18]. The risks were 
suggested to be as high as 12% during the first 25 years after diagnosis. One study of 
                                              
6 Cancer that starts in the lymphocytes (white blood cells) 
29 
 
a larger patient cohort concerning secondary cancer7 following treatment of a primary 
childhood cancer is the Childhood Cancer Survival Study (CCSS), consisting of 14 363 
5-year (at least) survivors of childhood cancer treated between 1970 and 1986 [72]. 
The study showed that radiotherapy increased the risk of all secondary cancers, with 
relationships between secondary cancer risk and dose estimated for specific cancer 
sites. This included a linear-exponential relationship between radiation dose and 
secondary thyroid cancer risk, where the risk increased up to doses of 29 Gy and then 
decreased for doses > 30 Gy, as well as a linear relationship between dose and risk of 
both secondary brain tumours and secondary breast cancer [72]. 
4.2 Predictive modelling 
Theoretical models can be used to extrapolate the risk estimation data from relevant 
epidemiological studies, making estimates from accidental irradiations applicable to 
radiation therapy doses and estimates from earlier and outdated radiotherapy treatment 
techniques applicable to modern radiation techniques, including proton therapy. The 
purpose of these models is to provide reasonable estimations of risk of radiation-
induced secondary cancer for the different techniques used in modern radiotherapy, for 
dose-ranges relevant for patients undergoing curative radiotherapy, and for site-
specific cancer induction in tissues with different radiosensitivities. The probability of 
secondary cancer induction as a function of dose, known as a dose-response 
relationship, forms the basis for these theoretical models. There is much debate on how 
this dose-response relationship is shaped for higher doses, with proposed shapes 
including a continuous linear increase with dose, the formation of a plateau where the 
cell kill is balanced by cell repopulation and repair, an exponential risk reduction due 
                                              
7 The reports from the CCSS use the term subsequent neoplasm rather than secondary cancer, but as most neoplasms turn into 
tumours, the term secondary cancer has been kept throughout this summary and only the statistics on malignant secondary 
neoplasms are listed 
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to the competition between cell mutation and cell kill, or alterations to these shapes due 
to fractionation effects (Figure 4.2 and Figure 4.3).  
4.2.1 Quantification of radiation-induced cancer risk 
The quantification of radiation-induced cancer risk in epidemiological studies is done 
by comparing the rate of cancer incidence in exposed populations to the rate of cancer 
incidence in unexposed populations [18]. This is also done for cancer mortality. The 
difference between the risk of cancer incidence with radiation exposure and the risk of 
cancer incidence without radiation exposure, i.e. the baseline risk, is called the excess 
absolute risk (EAR) (eq. (4.1)), and by dividing the EAR by the baseline risk one 
obtains the excess relative risk (ERR) (eq. (4.2)) [69]. For cancer incidence, the EAR 
is often expressed as the number of these cases per person-year (PY), whereas the ERR 
is dimensionless [18]. Both these terms are used in radiation epidemiology, often 
expressed per unit dose, and are dependent on variables such as sex (s), age at exposure 
(e), attained age (a), and time since exposure (y): 
where Re is risk in exposed subjects and Rn is risk in unexposed subjects [18, 69]. There 
is a danger of overrepresentation of changes for very small absolute risks which the 
EAR avoids, and is therefore the preferred measurement used for reporting risk in 
radiotherapy [17]. Because baseline risks can be different for one population compared 
to another, both ERR and EAR are used to make risk estimates obtained from one 
population applicable to the population of interest, known as risk transport [18]. This 
 𝐸𝐴𝑅(𝑠, 𝑒, 𝑎, 𝑦, 𝐷) =
𝑅𝑒(𝑠, 𝑒, 𝑎, 𝑦, 𝐷) − 𝑅𝑛(𝑠, 𝑒, 𝑎, 𝑦)
𝑃𝑌
 (4.1) 
 𝐸𝑅𝑅(𝑠, 𝑒, 𝑎, 𝑦, 𝐷) =
𝐸𝐴𝑅(𝑠, 𝑒, 𝑎, 𝑦, 𝐷)
𝑅𝑛(𝑠, 𝑒, 𝑎, 𝑦)
  
 =
𝑅𝑒(𝑠, 𝑒, 𝑎, 𝑦, 𝐷) − 𝑅𝑛(𝑠, 𝑒, 𝑎, 𝑦)




is usually done by combining the ERR and EAR estimates, weighted according to their 
relevance for each chosen organ site. The EAR and ERR calculations that are 
transported to the population of interest can be used to express the radiation risks in 
terms of lifetime risk, called lifetime attributable risk (LAR) [18, 73]. LAR gives the 
probability of cancer incidence (or mortality) for a person exposed to radiation from 
the age of exposure, e, added a risk-free latency period, L, to an attained age, a, of 100 
years: 
Here, S(a) is the survival function yielding the probability at birth to survive until the 
age a, and the ratio S(a)/S(e) is the probability of reaching age a on the condition of 
survival to age e (both S(a) and S(e) refer to the survival function of the unexposed 
population) [18, 73]. Equation (4.3) is an example of how LAR can be calculated based 
on EAR estimations [18]. EAR, ERR and LAR estimates can be used together with 
different dose-response relationships to model absolute, relative and lifetime risk of 
radiation-induced secondary cancer, respectively. 
4.2.2 Linear dose-response relationship and modifying factors 
The linear dose-response relationship obtained from the LSS cohort data (Figure 4.1) 
forms the basis for risk models used by committees concerned with radiation protection 
(e.g. the International Commission on Radiological Protection (ICRP) and BEIR) [74]. 
The LSS data is related to high doses and high dose-rates which can overestimate the 
radiation risks associated with low doses8 and low dose-rates for low-LET radiations 
[5, 18]. The risk estimates for exposure to high doses and dose-rates are therefore 
divided by a dose and dose-rate effectiveness factor (DDREF) to give the risk estimates 
relevant for exposure to low doses and dose-rates (recommendations are e.g. a DDREF 
                                              
8 Low dose is defined by the BEIR VII report as doses ranging from near zero to around 0.1 Sv of low-LET radiation 






of 2 for doses below 0.2 Gy at any dose-rate and for higher doses at dose-rates less than 
0.1 Gy/h (ICRP) and maximum 3 for tumour induction based on available data 
(UNSCEAR report from 1993) used together with linear dose-response models) [5, 18, 
69]. The DDREF may however not be applicable to radiotherapy as it is primarily used 
for doses and dose-rates much lower than the high (fractionated) doses and dose-rates 
in external-beam radiotherapy [16, 75]. As these linear dose-response models are 
developed with respect to radiation protection, and only have a clear validity at lower 
doses, they are not recommended to be used in risk estimations following radiotherapy 
for tissues receiving higher doses (> 2.5 Gy in Figure 4.1) [18, 69]. 
4.2.3 Linear-exponential dose-response relationship 
A bell-shaped dose-response relationship was proposed by Gray in the 1960s, where 
the risk of cancer incidence increases in proportion to cell mutation induced in normal 
cells for a lower dose-range, and then falls off at higher dose-ranges due to the increase 
in the probability of killing these mutated cells [5]. The relationship describing this 
competition between carcinogenic mutation induction and cell kill is also referred to as 
the linear-exponential dose-response relationship [76], and the UNSCEAR reports 
from 1993 and 2000 include a version of this (called the competition model) based on 
the LQ model: 
where D is the radiation dose, and the LQ parameters α1 and β1 represent the effect of 
carcinogenic mutation induction, and α2 and β2 represent the effect of cell killing [17]. 
When the radiation dose is low, equation (4.4) reduces to a linear dose-response 
relationship (Effect ≈ α1D), which corresponds to that observed for e.g. the LSS cohort, 
with α1 describing the rate of secondary cancer incidence for lower doses. This linear-
exponential dose-response relationship has been observed both for the induction of 
leukaemia in the LSS cohort and for site-specific cancer induction in certain patient 





cohorts [17]. Modifications to the dose-response relationship in equation (4.4) has been 
done by Schneider et al. (2005) (Figure 4.2) [76], with the linear-exponential dose-
response relationship as a function of dose (eq. (4.5)) and employing the EAR to this 
relationship (eq. (4.6)):  
Here, the organ-specific cancer incidence rates β, also referred to as the initial slope 
(i.e. the slope of the dose-response curve at low doses, described by the LSS cohort), 
is given in units of per 10 000 PY per Gy, 𝐸𝐴𝑅𝑜𝑟𝑔 is given in units of per 10 000 PY 
and 𝛼𝑜𝑟𝑔 is an organ-specific cell sterilisation parameter [76]. Relating this version of 
the linear-exponential dose-response relationship to epidemiological data, the β values 
were obtained from the UNSCEAR report of 2000 and the 𝐸𝐴𝑅𝑜𝑟𝑔 and D values were 
obtained using data from epidemiological studies on Hodgkin’s patients treated with 
(fractionated) radiotherapy. All these values were then used in equation (4.6) to 
determine the 𝛼𝑜𝑟𝑔 parameter values.  
Another variation of this dose-response relationship was introduced by Schneider et al. 
(2011) to account for the effects that can result from fractionation schemes used in 
radiotherapy (Figure 4.3 – here called the bell-shaped dose-response relationship in 
accordance with literature) [77]. This was done by having the 𝛼𝑜𝑟𝑔 parameter 
proportional to the number of cells that is reduced by cell killing and defined using the 
LQ model with the α and β parameters from equation (3.1): 
 𝑓(𝐷) = 𝐷𝑒−𝛼𝑜𝑟𝑔𝐷 (4.5) 
 𝐸𝐴𝑅𝑜𝑟𝑔 = 𝛽𝐷𝑒−𝛼𝑜𝑟𝑔𝐷 (4.6) 






Here, the fractionation schedule is implemented by the prescribed target dose, DT, and 
the fractionation dose, dT. As different tissues have different α/β values, equation (4.7) 
can be rearranged to account for this: 
Thus, the α parameter values can be determined for different α/β values [78].  
4.2.4 Plateau dose-response model 
The bell-shaped dose-response relationship differentiates from the linear-exponential 
dose-response relationship in equation (4.6) as it accounts for fractionation schemes 
employed in radiotherapy. However, it does not account for the cell repopulation 
effects that can occur during fractionated radiotherapy. The balance between cell kill 
and cell repopulation can result in a dose-response relationship that levels off in a 
continuous plateau for higher doses. This type of plateau dose-response relationship 
has been described by Schneider and Kaser-Hotz (2005) (Figure 4.2) [79], based on a 
model by Davis from 2004 [80], as a function of dose (eq. (4.9)), and employing the 
EAR to this relationship (eq. (4.10)) using the same variables as for the linear-
exponential dose-response relationship in equation (4.6): 
The 𝛿𝑜𝑟𝑔is an organ-specific model parameter, obtained in the same way as the 𝛼𝑜𝑟𝑔 
parameter from equation (4.6) [79]. The 𝛿𝑜𝑟𝑔 parameter values were thus determined 
based on the Hodgkin’s patient cohort values for 𝐸𝐴𝑅𝑜𝑟𝑔 and D, as well as the 𝛽 values 
which were obtained from the UNSCEAR report of 2000 and from the LSS cohort 
study by Thompson et al. (1994) [81]. The plateau dose-response relationship can also 
















account for fractionation effects and tissue types by representing the 𝛿𝑜𝑟𝑔 parameter in 
the same way as the 𝛼𝑜𝑟𝑔 parameter with equation (4.8) and finding the α parameter 
values for the plateau dose-response relationship (Figure 4.3) [77]. 
4.2.5 Full model dose-response relationship 
To account for the cases of cell repopulation effects that are somewhere between the 
full repopulation effect from the plateau dose-response relationship and no 
repopulation effect from the linear-exponential (or bell-shaped) dose-response 
relationship, Schneider (2009) [82] developed a mechanistic model for a dose-response 
relationship that includes a repopulation/repair parameter, R, to determine the size of 
the repopulation effects. This is hereafter referred to as the full model (Figure 4.3), with 
the dose-response relationship shown as a function of dose in equation (4.11), and 
employing the EAR and parameters used by Schneider et al. (2011) in equation (4.12): 
Here, the 𝛼′ parameter in equation (4.11) is represented as in equation (4.8) to account 
for cell killing, fractionation and different tissue types (i.e. α/β values) [77]. As for 
equation (4.12), the β values are the initial slopes for the LSS cohort taken from Preston 
et al. (2007) [83] in units of (10 000 PY-Gy)-1, and µ is a modifying function containing 
population dependent variables: 
where agex is age at exposure, agea is attained age and γe and γa are age modifying 
parameters for the LSS cohort at age of exposure of 30 and attained age of 70 years 





(1 − 2𝑅 + 𝑅2𝑒𝛼




 𝐸𝐴𝑅𝑜𝑟𝑔(𝐷, 𝑎𝑔𝑒𝑥, 𝑎𝑔𝑒𝑎) = 𝛽 𝑓(𝐷) 𝜇(𝑎𝑔𝑒𝑥, 𝑎𝑔𝑒𝑎) (4.12) 








i.e. if no cell repopulation occurs, the dose-response relationship becomes linear-
exponential (or bell-shaped): 
And deriving equation (4.11) in the limit of R = 1, i.e. if full cell repopulation occurs, 
the dose-response relationship turns into a plateau one: 
To derive the values of α and R for different organs at risk, Schneider et al. (2011) used 
a combined fit of the LSS cohort and a Hodgkin’s patient cohort [77].  
 
Figure 4.2: Illustration of dose-response relationships for solid cancer 
excess absolute risk as a function of homogeneous dose. Parameter 
values are chosen according to Schneider and Kaser-Hotz (2005) [79]. 










Figure 4.3: Illustration of dose-response relationships for lung cancer 
excess absolute risk as a function of homogeneous dose. Parameter 
values are chosen according to Schneider et al. (2011) [77]. 
4.2.6 The organ equivalent dose concept 
Inhomogeneous dose distributions occur in both proton and photon therapy and 
becomes a problem when one employs the average organ dose in secondary cancer risk 
estimations. This may lead to erroneous risk estimates as it does not account for the 
cell sterilisation effects that can occur at higher doses. Schneider et al. (2005) proposed 
a solution to this problem by implementing the concept of organ equivalent dose (OED) 
when estimating the risk of radiation-induced secondary cancer [76]. This concept 
states that any dose distribution within an organ is equivalent and corresponds to the 
same OED if it causes the same radiation-induced risk of cancer incidence, allowing 
this risk to be estimated from inhomogeneous three-dimensional dose distributions. 
The dose in each voxel can therefore be converted into so-called risk equivalent dose 
(RED), which represents the dose-response relationship function f(D) from the 
equations in chapters 4.2.3-4.2.5 [77]. As the RED only yields the risk of radiation-
induced secondary cancer as a function of dose in each voxel inside an organ, the OED 
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concept can either be applied to obtain risk estimates for the whole organ by taking the 
sum over all RED calculation points (N), representing the same constant organ volume 
(eq. (4.16)), or determined for an organ of total volume VT, based on the RED and the 
dose volume histogram, V(D), for that organ (eq. (4.17)). 
 
Thus, the OED is the dose-response relationship (or RED) weighted dose variable 
averaged over the whole organ volume [77]. For a linear RED weighted dose, the OED 


















5. Material and methods 
5.1 Patient data and treatment planning 
5.1.1 Patient data 
The patient cohort selected for this thesis consisted of 10 paediatric medulloblastoma 
patients, 5 boys (8-12 years old) and 5 girls (5-9 years old). All patients had received 
cranio-spinal irradiation (CSI) as a part of the treatment. All structures of relevance in 
this thesis were individually delineated by an experienced oncologist. This included 
the clinical target volume (CTV), consisting of the brain and spinal canal, which was 
further used to define the planning target volumes (PTVs), as well as the organs at risk 
that were chosen for radiation-induced secondary cancer risk estimations. 
The sites included for estimation of secondary cancer risk following proton therapy 
were the lungs and the thyroid. These sites were chosen for the following reasons: 
• Both sites are at risk of receiving high doses during CSI treatment of 
medulloblastoma as they are placed close to the target volume (Figure 5.1) 
o The lungs and thyroid are located distally and laterally to the target 
volume and beam direction, in the vicinity of the higher LET components 
associated with the distal part of the SOBP, and thereby at risk of 
receiving doses with increased probability of RBE values larger than 1.1 
• Photon CSI can cause significant dose delivered to these two structures, which 
can be largely avoided with proton CSI and is therefore particularly beneficial 
for this patient group with regards to long term effects and secondary cancer [4] 
o This also makes it interesting to investigate risk predictions for these 
organs made by RBE values beyond 1.1 
• Both sites (thyroid especially) have shown great variations in risk based on sex 
and age of the patient [18] 
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• Radiation exposure, especially during childhood, is a well-established factor in 
increasing thyroid cancer incidence, which is also the second most common 
cancer in young women (after breast cancer) [84] 
• Lung cancer has a high mortality rate, especially if diagnosed at a late stage [85] 
The proton CSI treatment plans with both constant and variable RBE described in the 
next two sections were all created prior to this thesis. These treatment plans were then 
used together with each of the dose-response relationships in chapters 4.2.2-4.2.5 to 
estimate the risk of secondary cancer induction for proton therapy, employing the OED 
concept to account for inhomogeneous dose distributions in normal tissues [17]. 
5.1.2 Treatment planning 
For all the patients in the cohort, the CSI treatment plans were optimised in the Eclipse 
treatment planning system (Varian Medical Systems, Palo Alto, CA, USA) using the 
conventional radiotherapy dose prescription for standard risk medulloblastoma: 23.4 
Gy delivered in 13 fractions to the CTV. Using the principles of proton RBE related to 
the isoeffective absorbed doses for protons and photons (eq. (3.2)) discussed in chapter 
3.3, the dose and LET distributions were converted into distributions of RBE-weighted 
doses. From this, a biologically weighted dose of 23.4 Gy(RBE) was used for the 
proton plans based on the clinical RBE of 1.1. The technique used for the proton CSI 
treatment delivery was intensity-modulated proton therapy (IMPT) with pencil beam 
scanning. 
5.1.3 Variable RBE models 
The treatment plans were recalculated using FLUKA Monte Carlo code [86, 87] 
coupled to in-house python based scripts [88] to obtain LETd, RBE, and RBE-weighted 
doses for the four variable RBE models used in this thesis: LET-weighted dose, the 
McNamara model, the Rørvik model and the Wilkens model; further details can be 
found in Rørvik et al. (2018) [63] and SOBPs presented in Figure 3.3. An example of 
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the dose distribution with constant and variable RBE is shown for one of the patients 
in Figure 5.1. 
LET-weighted dose is often referred to as the Unkelbach model as it was proposed by 
Unkelbach et al. in 2016 [62]. The model is here referred to as LET-weighted dose 
(abbreviated LWD) because it uses the LET distribution in the proton plan directly, 
independent of tissue or patient-specific RBE. The model assumes an increase in RBE 
with increasing LET, and do not account for the assumption of a steeper RBE increase 
with LET for normal tissues with low (α/β)x values than for tumours with higher (α/β)x 
values. 
The McNamara model [60] shows a linear increase in RBE with LETd and increasing 
RBE with decreasing (α/β)x values. The calculations using the McNamara model in this 
thesis has been done with (α/β)x = 2 Gy (abbreviated MCN2Gy) and (α/β)x = 10 Gy 
(abbreviated MCN10Gy). 
The Rørvik model [61] is the only variable RBE model in this thesis with a non-linear 
RBE-LETd relationship. As with the McNamara model, the Rørvik model accounts for 
RBE variations with tissue type, which is why the calculations using this model has 
also been done with (α/β)x = 2 Gy (abbreviated RØR2Gy) and (α/β)x =10 Gy 
(abbreviated RØR10Gy). 
The Wilkens model [39] is based on data points from in vitro experiments using V79 
cell lines. The model (abbreviated WIL) has a linear dependency of RBE on LETd 
(RBE increasing with increasing LETd up to 20 keV/µm), and also describes RBE as a 
function of dose and tissue specific parameters for protons. The model has a fixed (α/β)x 




Figure 5.1: Dose distribution in patient 4 (8-year-old female) with constant RBE of 1.1 (left) and 
variable RBE model (right) for contoured organs at risk – lungs (top) and thyroid (bottom). 
5.2 Modelling risk of radiation-induced cancer  
In this thesis, two approaches were used to estimate the risk of radiation-induced (lung 
and thyroid) cancer for each patient. The first approach was to calculate the LAR based 
on the OED concept and the dose-response relationships by Schneider et al. (2005) [76, 
79]. This was done for both lung and thyroid. The second approach was to calculate 
the EAR using the OED concept for the lungs using the dose-response relationships by 
Schneider et al. (2011) [77]. No EAR thyroid model was reported from the latter. 
5.2.1 Obtaining the OED 
The RBE-weighted dose distributions in the proton plans for each RBE model (both 
clinical RBE of 1.1 – hereby referred to as RBE1.1 – and the four variable RBE models) 
were recalculated to RED distributions using an in-house developed python script [88]. 
The python script was modified to calculate the RED for each organ at risk and each 
RBE model using the dose-response relationships in chapters 4.2.2-4.2.5. The resulting 
RED-weighted proton plans were then imported to 3D Slicer (version 4.8.0) [89] where 
the dose volume histograms (DVHs) could be created from the RED distributions for 
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the lungs and thyroid of each patient from all RBE models, thus yielding the OED 
according to eq. (4.17) for each organ. The RED distributions obtained for each organ, 
RBE model and risk model was used together with the CT images of one of the patients 
to illustrate the respective RED distributions in each organ. 
5.2.2 Lifetime attributable risk calculations 
To calculate the LAR for the lungs and thyroid of each patient, the OED was estimated 
for each organ with respect to each RBE model and each of the linear, linear-
exponential, and plateau dose-response relationship functions in equations (4.5) and 
(4.9) using organ-specific parameters for each organ at risk (Table 5.1). The OED 
values obtained using 3D Slicer were then multiplied with a risk coefficient, l, derived 
from table 12D-1 in BEIR VII report [18] to yield the LAR in % for each patient and 
organ at risk: 
The table values in the BEIR VII report are given as LAR per 100 000 persons per 0.1 
Gy dose, divided by a DDREF of 1.5. As the use of a DDREF is not appropriate for 
the high doses and dose-rates in radiotherapy (see chapter 4.2.2), the DDREF was 
removed from the calculations. Thus, the following equation was used to derive the 
risk coefficient l: 
As the table values were given for the ages at exposure 0, 5, 10 and 15 years, the values 
for ages at exposure not listed were derived through linear interpolation. The resulting 
values for the risk coefficient l are listed in Appendix A for lungs (Table A.1) and in 
Appendix B for thyroid (Table B.1). To represent the uncertainties in the risk estimates, 
a 95% confidence interval was calculated for both organs using the procedure 
 𝐿𝐴𝑅 = 𝑙 ∙ 𝑂𝐸𝐷𝑜𝑟𝑔 (5.1) 
 𝑙 = 100% ∙
𝑡𝑎𝑏𝑙𝑒 𝑣𝑎𝑙𝑢𝑒
100 000 𝑝𝑒𝑟𝑠𝑜𝑛𝑠






explained in Annex 12C of the BEIR VII report and based on uncertainty values listed 
in the BEIR report (excluding the uncertainty related to the DDREF) [18]. 




Lung 0.129 0.15 
Thyroid 0.033 0.69 
 
To make a general comparison of estimated LAR of the lungs and the thyroid for the 
whole patient cohort, the median value was calculated for each RBE model and each 
dose-response relationship. And lastly, the ratio of the LAR estimates made by the 
variable RBE models were normalised to the LAR estimates made by RBE1.1 to find 
the relative change in LAR of secondary lung and thyroid cancer with the variable RBE 
models. The median value was calculated for comparison of predicted relative change 
in LAR between the variable RBE models across the different dose-response 
relationships. 
5.2.3 Excess absolute risk calculations 
To calculate the EAR for each patient and organ at risk, the OED was estimated with 
respects to each RBE model and each of the functions for the bell-shaped, plateau, and 
full model dose-response relationship in equations (4.11), (4.14) and (4.15), as well as 
for a linear dose-response relationship, using site-specific model parameters. As there 
was no reported thyroid model, the calculations could only be done for the lungs (with 





Table 5.2: Lung model parameters from table 4 in Schneider et al. (2011) [77]. 
RED function α [Gy-1] 
Full model (eq. (4.15)) 0.042 
Bell-shaped (eq. (4.11)) 0.022 
Plateau (eq. (4.14)) 0.056 
 
The patient fractionation dose of 1.8 Gy(RBE) was used to find 𝛼′ according to 
equation (4.8). As Schneider et al. (2011) assumes α/β = 3 Gy for all tissues, this was 
also done here for lung tissue. The resulting OED values obtained using 3D Slicer was 
multiplied with a risk coefficient, r, to yield the EAR for the lungs of each patient: 
where the risk coefficient, r, contains the information from the β- and µ-values in 
equation (4.12): 
As with Schneider et al. (2011), the β-values, along with a 90% confidence interval to 
represent the uncertainties in the risk estimates, were taken from Preston et al. (2007) 
[83] using the male/female values instead of the sex-averaged, and transferred to a 
Western population by using the ERR-EAR weighting factor (established according to 
ICRP 103) for lungs of 1.07 from Schneider et al. (2011) (Table 5.3) [77]. To adjust 
the EAR estimations to fit the patient cohort, the modifying function µ was calculated 
based on equation (4.13) using patient data age at exposure (agex) and attained age 
 𝐸𝐴𝑅𝑜𝑟𝑔 = 𝑟 ∙ 𝑂𝐸𝐷𝑜𝑟𝑔 (5.3) 
 𝑟 = 𝛽𝐸𝐴𝑅 ∙ 𝜇(𝑎𝑔𝑒𝑥, 𝑎𝑔𝑒𝑎)  








(agea) = average life expectancy in Norway 2017 (Table 5.3) [90]. The resulting values 
for the risk coefficient r are listed in Appendix C (Table C.1).  
Table 5.3: Parameters for EAR calculations: β-values with a 90% confidence interval (in 
parenthesis) for lungs from Preston et al. (2007), transported to a Western population by 
weighting factor from Schneider et al. (2011), and average life expectancy in Norway 2017 
as attained age. 
 Male Female 
𝛽𝐸𝐴𝑅  6.420 (2.461, 11.770) 9.737 (6.848, 12.840) 
Attained age (agea) 80.91 84.24 
 
As with the LAR values, the median EAR for the whole patient cohort was calculated 
for each RBE model and each dose-response relationship for a general comparison. 
And lastly, the ratio of the EAR estimates made by the variable RBE models were 
normalised to the EAR estimates made by RBE1.1 to find the relative change in EAR 
of secondary lung cancer with the variable RBE models. The median value was 
calculated for comparison of predicted relative change in EAR between the variable 







The calculated risk estimates for the patient cohort, both individual and collective, 
regarding radiation-induced secondary lung and thyroid cancer are presented in this 
chapter, with the risk model (LAR and EAR) results for each organ (lungs and thyroid) 
described separately. 
6.1 Lifetime attributable risk 
To illustrate the difference between the three dose-response relationships, the LAR as 
a function of homogeneous proton dose is shown for one of the patients in the cohort, 
in Figure 6.1. 
  
Figure 6.1: Lifetime attributable risk of secondary lung cancer (left) and thyroid cancer (right) as a function of 
homogeneous dose estimated for patient 4 (8-year-old female), using the linear (grey line), linear-exponential 
(green line) and plateau (blue line) dose-response relationship. The prescription dose to the target volume is 
23.4 Gy(RBE) and the contributions of higher doses are therefore small for the patients in this cohort; the 
higher dose levels are included only to illustrate the differences between the dose-response relationships at 
these dose levels. 
Both plots show that the linear dose-response relationship gives the highest risk for 
radiation doses > 2 Gy(RBE) for lungs and > 3 Gy(RBE) for thyroid. The differences 
between the two organs using the two non-linear dose-response relationships are due 
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to the differences in the values for the organ-specific cell sterilisation parameter 𝛼𝑜𝑟𝑔 
and the organ-specific model parameter 𝛿𝑜𝑟𝑔 (Table 5.1). Here, the peak of the linear-
exponential dose-response relationship risk prediction is reached at about 7 and 30 
Gy(RBE) for lungs and thyroid, respectively. The secondary thyroid cancer risk 
predictions for the plateau dose-response relationship reaches the plateau already at 
about 5 Gy(RBE), whereas the dose level at which the risk predictions for secondary 
lung cancer reach this plateau is not present in the dose range displayed in the figure. 
Using both the RBE models and the dose-response relationships, the estimated OEDs 
and LARs for each of the ten patients in regards to secondary lung cancer are shown in 
Figure 6.2 and Figure 6.3, respectively. 
 
Figure 6.2: Organ equivalent doses for the lungs in Gy(RBE) using the different RBE 
models and dose-response relationships. The results are shown for patient 1-10 in 




Figure 6.3: Lifetime attributable risks of secondary lung cancer in % using the different RBE 
models and dose-response relationships. The results are shown for patient 1-10 in 
succession from left to right for each RBE model. 
The highest OED values were found among female patients 1 and 4 (5 and 8 years of 
age, respectively) and male patients 6 and 8 (both 8 years old), while the lowest OED 
values were found among male patients 7 and 9 (8 and 11 years of age, respectively). 
The distinction between the three dose-response relationships were quite clear for the 
ranges of OED estimates: 0.76 to 1.37 Gy(RBE) (linear-exponential), 1.20 to 2.74 
Gy(RBE) (plateau), and 2.17 to 6.29 Gy(RBE) (linear). Each individual OED value is 
listed in Table A.2 in Appendix A. 
All secondary cancer risk dose-response relationships showed a higher LAR of 
radiation-induced lung cancer for the variable RBE models compared to the constant 
RBE1.1. The risks were highest for the WIL and the MCN2Gy models for the linear 
model, while the RØR2Gy and the MCN2Gy models gave the highest risks for the linear-
50 
 
exponential and plateau models, respectively. With respect to each dose-response 
relationship applied, the highest LAR estimates were made with the linear model, 
followed by the plateau model, and with the linear-exponential model yielding the 
lowest risk estimates. This was the case for all patients, independent of RBE model 
used. Across all dose-response relationship applied, the highest LARs were found for 
patient 1 (5-year-old female) and the lowest LARs were found for patient 9 (11-year-
old male). Collectively, the LARs of secondary lung cancer were higher for the female 
patients (1-5) compared to the male patients (6-10). Each individual LAR value is listed 
in Table A.3 in Appendix A. 
The median LAR values for the patient cohort are shown in Figure 6.4. Each median 
LAR estimate, including the range consisting of the minimum and maximum LAR, is 
listed in Table A.4 in Appendix A. The RBE1.1 model had the lowest median risk of 
secondary lung cancer, regardless of dose-response relationship applied. For the 
different dose-response models, the highest median risk predictions were with the WIL 
model (linear), the RØR2Gy model (linear-exponential), and the MCN2Gy model 
(plateau). The linear-exponential dose-response relationship had the overall lowest 
median risk estimates for all RBE models, where the RØR2Gy and MCN2Gy models 
showed the highest median risk increase of 10% relative to the RBE1.1 (Figure 6.5). For 
the plateau model, the highest median relative LAR was 19%, and a 30% median 
relative LAR for the linear model. The two latter relative LARs were predicted by the 
MCN2Gy model, which were followed by slightly smaller increases predicted by the 
WIL and RØR2Gy models, in succession with the linear model and equal with the linear-
exponential model. The variations in the estimated relative risks were highest for these 
three variable RBE models, where the largest ranges were from 24 to 33% (linear, 
WIL), from 7 to 16% (linear-exponential, RØR2Gy), and from 15/16 to 21/22% (plateau, 
WIL/MCN2Gy). The median relative LARs predicted by the remaining variable RBE 
models were much lower, with much smaller variations in predicted relative risks. The 
overall lowest median predictions were given by the remaining variable RBE models, 
where all median relative LARs were under 3% for the RØR10Gy model. Each median 
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relative LAR, including the range consisting of minimum and maximum relative LAR, 
is listed in Table A.5 in Appendix A. 
 
Figure 6.4: Median lifetime attributable risk of radiation-induced lung cancer in % of ten 
patients for each RBE model and each dose-response relationship. The error bars 




Figure 6.5: The ratio between the variable RBE model LAR estimates and the LAR 
estimates made by RBE1.1 for each dose-response model. The points are the median ratio 
values of ten patients with error bars representing the range in terms of minimum and 
maximum LAR ratio. 
Figure 6.6 shows an example of the RED distribution in patient 4 for each of the three 
dose-response relationships using the MCN2Gy model. Both the linear and the plateau 
dose-response relationship predicted the highest risk of secondary lung cancer to be 
located in the lung tissue close to the target volume, with the plateau dose-response 
relationship showing a larger high-RED distribution (although with lower values) 
further away from the target volume than the linear. The linear-exponential dose-
response relationship, however, predicted the highest risk in a more ring-shaped area 
further away from the target volume. This distance from the target volume was 






Figure 6.6: Distribution of risk equivalent dose (RED) in the lungs of patient 4 (8-year-old female) 
with a variable RBE model (MCN2Gy) using the linear (top), linear-exponential (bottom left) and 
plateau (bottom right) dose-response relationship. RED is given in units of Gy(RBE) which is 





The estimated OEDs and LARs for each patient regarding secondary thyroid cancer 
are shown in Figure 6.7 and Figure 6.8, respectively. 
 
Figure 6.7: Organ equivalent doses for thyroid in Gy(RBE) using the different RBE models 
and dose-response relationships. The results are shown for patient 1-10 in succession from 




Figure 6.8: Lifetime attributable risks of secondary thyroid cancer in % using the different 
RBE models and dose-response relationships. The results are shown for patient 1-10 in 
succession from left to right for each RBE model. 
The higher OEDs were found for the linear and linear-exponential dose-response 
relationships. The variations between OEDs were also much larger for these two dose-
response relationships, ranging from 1.24 to 11.37 Gy(RBE) (linear) and from 1.07 to 
7.33 Gy(RBE) (linear-exponential), compared to the plateau dose-response 
relationship, which predicted the overall lowest OEDs ranging from 0.61 to 1.44 
Gy(RBE). Each individual OED value is listed in Table B.2 in Appendix B. 
All three dose-response relationships showed an overall higher LAR of radiation-
induced secondary thyroid cancer for the variable RBE models compared to the RBE1.1. 
The risks were highest for the WIL and the MCN2Gy models using the linear dose-
response relationship, while the MCN2Gy model generally gave the highest risks for 
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both the linear-exponential and the plateau dose-response relationships. For all 
patients, regardless of RBE model employed, the predicted LARs of secondary thyroid 
cancer were highest using the linear dose-response relationship, followed by the linear-
exponential, and with the plateau dose-response relationship predicting the lowest 
risks. For all dose-response relationship applied, the highest LARs were found for 
female patients 1 and 2 (5 and 6 years of age, respectively) and the lowest LARs were 
found for patient 6 (8-year-old male). Overall, the female patients had higher estimated 
LARs of secondary thyroid cancer compared to the male patients. Each individual LAR 
value is listed in Table B.3 in Appendix B. 
The median LAR values for the patient cohort are displayed in Figure 6.9 (each 
individual value with range is listed in Table B.4 in Appendix B). The RBE1.1 model 
had the lowest median risk of secondary thyroid cancer for each of the dose-response 
relationships. The MCN2Gy model had the highest median risk estimates for all three 
dose-response relationships, with the WIL model estimating an equally high median 
risk only for the linear dose-response relationship. The plateau model had the overall 
lowest median risk estimates for all RBE models, as well as the smallest increase in 
LAR with the variable RBE models relative to RBE1.1 (Figure 6.10). Here, the highest 
median relative LAR was predicted by the MCN2Gy model of only 9%, as opposed to 
the 36% and 47% median relative LARs for the linear-exponential model (MCN2Gy) 
and the linear model (WIL), respectively. These two variable RBE models, followed 
closely by the RØR2Gy model, showed the largest variations in relative LAR 
predictions. The median relative LARs were much lower for the remaining variable 
RBE models, which also had much smaller variations in their relative LAR estimations. 
The RØR10Gy model predicted the overall lowest median relative LAR, as well as 
variations in the predicted relative risks, with 5% (range: 3 to 10%) for the linear model, 
4% (range: 2 to 9%) for the linear-exponential model, and only 1% (range: 0 to 5%) 
for the plateau model. Each median relative LAR, with the range of min and max 




Figure 6.9: Median lifetime attributable risk of radiation-induced thyroid cancer in % of ten 
patients for each RBE model and each dose-response relationship. The error bars 




Figure 6.10: The ratio between the variable RBE model LAR estimates and the LAR 
estimates made by RBE1.1 for each dose-response model. The points are the median ratio 
values of ten patients with error bars representing the range in terms of minimum and 
maximum LAR ratio. 
Figure 6.11 shows an example of the RED distribution in patient 4 for each of the three 
dose-response relationships using the MCN2Gy model. All three dose-response 
relationships predicted the risk of secondary thyroid cancer to be highest near the target 
volume on the left side of the body (right side in the plots) where the thyroid is closest 
to the target. The spatial risks of the linear and linear-exponential dose-response 
relationship show very little difference in RED distribution and values, with a small 
higher-RED region at the edge of the thyroid and mostly lower-RED values in the rest 
of the organ, whereas the plateau dose-response relationship show a more even 
decrease in RED with distance from the target volume. The RED values are also 





Figure 6.11: Distribution of risk equivalent dose (RED) in the thyroid of patient 4 (8-year-old female) 
with a variable RBE model (MCN2Gy) using the linear (top), linear-exponential (bottom left) and 
plateau (bottom right) dose-response relationship. RED is given in units of Gy(RBE) which is 
proportional to the LAR in each voxel. The CT scan has been zoomed inn to clearer see any 
difference in RED distribution (original size displayed in Figure 5.1). 
6.2 Excess absolute risk 
The EAR of radiation-induced lung cancer as a function of homogeneous dose is shown 
in Figure 6.12 to illustrate the difference between the four dose-response relationships 




Figure 6.12: Excess absolute risk of secondary lung cancer as a function of 
homogeneous dose in [/10000 PY] estimated for patient 4 (8-year-old female), using 
the linear (grey line), bell-shaped (green line), plateau (blue line) and full model (red 
line) dose-response relationship. The prescription dose to the target volume is 23.4 
Gy(RBE) and the contributions of higher doses are therefore small for the patients in 
this cohort; the higher dose levels are included only to illustrate the differences 
between the dose-response relationships at these dose levels. 
The EAR is similar for all dose-response relationships up to about 2 Gy(RBE). For 
doses higher than 2 Gy(RBE), the EAR is highest for the linear dose-response 
relationship, followed by the bell-shaped, plateau and full model in succession from 
highest to lowest risk up to about 21 Gy(RBE). For doses exceeding approximately 21 
and 26 Gy(RBE), the full model predicts higher risks than the plateau and the bell-
shaped dose-response relationships, respectively. The plateau dose-response 
relationship also yields higher risk predictions than the bell-shaped above around 28 
Gy(RBE). 
Employing each of the RBE models and each of the four dose-response relationships, 
the estimated OED and EAR of secondary lung cancer for each patient are shown in 




Figure 6.13: Organ equivalent doses for the lungs in Gy(RBE) using the different RBE 
models and dose-response relationships. The results are shown for patient 1-10 in 




Figure 6.14: Excess absolute risks of secondary lung cancer in (10000 PY)-1 using the 
different RBE models and dose-response relationships. The results are shown for patient 
1-10 in succession from left to right for each RBE model. 
As with the LAR of secondary lung cancer, the highest OED values were found for the 
female patients 1 and 4 and for the male patients 6 and 8, and the lowest OED values 
were found for patients 7 and 9. There was however a less clear distinction between 
the non-linear dose-response relationships for the ranges of OED estimates for EAR of 
secondary lung cancer compared to the previous LAR (lung) calculations (the linear 
values were of course identical). Here, the lower OED values for the three non-linear 
dose-response relationships were rather close and ranged from 1.49 (RBE1.1 for patient 
9 using the full model dose-response relationship) to 3.90 Gy(RBE) (MNC2Gy for 
patient 4 using the bell-shaped dose-response relationship). Each individual OED value 
is listed in Table C.2 in Appendix C. 
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For the estimated EARs of secondary lung cancer, the variable RBE models all showed 
higher risk estimates compared to the constant RBE1.1 model. Overall, the risk estimates 
were highest for the MCN2Gy model for all four dose-response relationships, with the 
only exception being the three higher risk estimates for patients 4-6 by the WIL model 
using the linear dose-response relationship. Across all RBE models, the highest risks 
were estimated using the linear dose-response relationship for all the patients in the 
cohort. The three non-linear dose-response relationships had more similar risk 
estimates, where the bell-shaped have the highest risks of the three, followed by the 
plateau, and with the full model estimating the lowest risks of all four dose-response 
relationships. Collectively, the EAR estimates were higher for the female patients 
compared to the male patients for all RBE models and dose-response relationships 
applied. The EAR estimates showed the same tendencies as the estimated LAR values 
of secondary lung cancer, with almost twice as high risk estimates for 8-year-old female 
patient 4 compared to 8-year-old male patient 6. Any relationship between the EAR 
estimates and the patient age could not be determined for either of the patients in the 
cohort. Each individual EAR value is listed in Table C.3 in Appendix C. 
The median EAR values for the patient cohort are presented in Figure 6.15 (and listed 
along with the range in Table C.4 in Appendix C). The RBE1.1 model had the lowest 
median risk of secondary lung cancer for all four dose-response relationships. The WIL 
model had the highest median risk estimate for the linear model and the MCN2Gy model 
had the highest median risk estimates for all three non-linear models. Of the four dose-
response models, the full model had the overall lowest median risk estimates for all 
RBE models, and the linear model had the highest. Regarding the median relative EAR 
with respect to each dose-response relationship (Figure 6.16), the MCN2Gy model 
predicted the highest median risk increase relative to RBE1.1 for all four dose-response 
relationships, as well as the largest variations in estimates, with 31% median relative 
EAR for the linear model (ranging from 26% to 33%), 20% for the bell-shaped and 
plateau model (ranging from 17% to 24%), and 21% for the full model (ranging from 
18% to 24%). The WIL and RØR2Gy models, predicting the second and third highest 
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median relative EARs, respectively, had similar variations in estimates. The lowest 
relative EAR was made by the RØR10Gy model with respect to both median value and 
the range, with a median relative EAR of 2% for all dose-response relationships 
applied. Each median relative EAR, with the range of min and max values, is listed in 
Table C.5 in Appendix C. 
 
Figure 6.15: Median excess absolute risk of radiation-induced lung cancer in (10000 PY)-1 
of ten patients for each RBE model and each dose-response relationship. The error bars 




Figure 6.16: The ratio between the variable RBE model EAR estimates and the EAR 
estimates made by RBE1.1 for each dose-response model. The points are the median ratio 
values of ten patients with error bars representing the range in terms of minimum and 
maximum EAR ratio. 
Figure 6.17 shows an example of the RED distribution in patient 4 for each of the four 
dose-response relationships using the MCN2Gy model. All four dose-response 
relationships predicted the highest risk of secondary lung cancer in the lung tissue 
closest to the target volume, with the highest RED values predicted by the linear dose-
response relationship and similar RED values predicted by the non-linear dose-
response relationships. In the RED distribution further away from the target volume, 
the linear dose-response relationship showed a steeper decrease in RED values than the 
three non-linear dose-response relationships. No clear ring-shaped RED distribution 
similar to the one in Figure 6.6 could be seen for any of the non-linear dose-response 





Figure 6.17: Distribution of risk equivalent dose (RED) in the lungs of patient 4 with a variable RBE 
model (MCN2Gy) using the linear (top left) bell-shaped (top right), plateau (bottom left) and full model 
(bottom right) dose-response relationship. RED is given in units of Gy(RBE) which is proportional 







The results have shown an overall increase in estimated radiation-induced secondary 
cancer risk with variable proton RBE compared to the generic value of 1.1. Depending 
on the choice of dose-response relationship, the median increase in risk estimates for 
the variable RBE models were 1 to 47% relative to the RBE of 1.1. The linear models 
with respect to both LAR and EAR predicted the highest risk with variable RBE 
compared to 1.1 for both organs at risk. The variations in risk estimates were also much 
larger for the linear models. The difference in risk variations between the non-linear 
dose-response relationships were dependent on the risk model applied, showing little 
variation for EAR estimates and larger variations for LAR estimates, especially for 
LAR of secondary thyroid cancer. The variations in risk estimates across the different 
RBE models were much smaller compared to those seen across the different dose-
response relationships. The validity of the absolute risk estimates therefore had a 
stronger dependency on dose-response relationship than RBE model applied. For the 
relative increase in risk, on the other hand, the variations in estimates were much 
smaller across all dose-response relationships applied, with the larger variations in 
relative risk predictions were seen across the variable RBE models used. This was also 
where the median relative risk estimates varied most across the different dose-response 
relationships. Thus, the validity of the relative increase in risk with variable RBE has 
an overall stronger dependency on the chosen variable RBE model than the chosen 
dose-response relationship. 
Most of the organ doses in these calculations exceeded the threshold value of 2.5 
Gy(RBE) where the risk estimates made by linear models start exceeding those made 
by the non-linear models (Figure 6.1 and Figure 6.12). The EAR estimates using the 
non-linear dose-response relationships were the most similar to each other of all non-
linear model estimates. The ranges of risk estimates were between 18 and 80 (10 000 
PY)-1 for the bell-shaped model, between 18 and 76 (10 000 PY)-1 for the plateau model 
and between 17 and 74 (10 000 PY)-1 for the full model. These similarities are due to 
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the plateau dose-response relationship falling off at higher doses similar to the bell-
shaped dose-response relationship, which differs from the plateau shape seen in the 
LAR dose-response curves for both lung and thyroid. Also, with the full model 
representing a combination of these two, it is not unexpected that the EAR estimates 
vary as little as they do between the non-linear dose-response relationships. Even 
though there is an agreement that paediatric medulloblastoma have a significant 
increase in risk of developing radiation-induced secondary cancer after radiotherapy, 
all LAR and EAR estimates in this thesis are relatively high compared to registered 
secondary cancers for this patient group [21-23]. There has been recorded a significant 
increase in risk of developing secondary thyroid cancer where 2 out of 379 patients 
developed thyroid cancer at 8 and 10 years after treatment in the study by Packer et al. 
(2013), and Strodtbeck et al. (2013) found a statistically significant relative risk of 
secondary thyroid cancer at least 5 years post treatment [22, 23]. However, the risks 
are still lower than the lowest median LAR estimate of secondary thyroid cancer of 
2.25% in this thesis, and as no records of observed secondary lung cancer was listed 
explicitly, it can be assumed that this risk was higher in this thesis as well. On the other 
hand, the follow-up time for the patients in these studies did not exceed 21 years and 
can therefore not provide extensive information regarding lifetime risks of secondary 
cancer induction, which could possibly be much higher due to the latency period of 
most solid cancers. 
Several differences in the predicted risks were seen between the variable RBE models 
for each of the dose-response relationships. Regarding the variations between the 
models with differences in chosen (α/β)x value, both the McNamara model and the 
Rørvik model predicted higher median absolute and median relative risks with (α/β)x 
= 2 Gy than with (α/β)x = 10 Gy. The Wilkens model also had some of the higher risk 
predictions in the results, and as this model uses (α/β)x = 3.76, i.e. higher (α/β)x value 
than the MCN2Gy and RØR2Gy models, this indicates that the risk does not necessary 
increase with lower (α/β)x values across models. Although there are no definite answers 
to the (α/β)x value of lung and thyroid tissue, there are indications in literature 
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suggesting that 3 Gy could be suitable. The thyroid has usually been given an (α/β)x  
value corresponding to late reacting tissue, whereas  (α/β)x  values for lung tissue have 
been listed in the form of range of 2.0-6.3 Gy, and 2.4-6.3 Gy, as well as a fixed 4.0 ± 
0.9 Gy [5, 91-93]. Therefore, arguments could be made for the higher validity of 
variable RBE models with (α/β)x values corresponding to late responding tissues rather 
than those with (α/β)x corresponding to early responding tissues of 10 Gy, increasing 
the importance of the larger relative risks predicted by the MNC2Gy, RØR2Gy and WIL 
models. The highest predicted median relative risks by these RBE models ranged from 
9 to 47%. Concerning other variable RBE model aspects, there seemed to be no clear 
difference between the risk predictions for the non-linear RBE-LETd relationship of 
the Rørvik model and those for the linear RBE-LETd relationships of the other variable 
RBE models, albeit the RØR10Gy predicting the lowest relative risks of all the variable 
RBE models, followed closely by the MCN10Gy and the LWD models. 
According to the BEIR VII report [18], the risk of radiation-induced lung and thyroid 
cancer is higher for females than for males, both for LAR and EAR estimations. This 
was also evident from the results in this thesis. In addition, the report shows an increase 
in LAR with decrease in age at exposure, of which these results did not show any clear 
indication. This was likely due to the individual size of the patients and thereby the 
dose distribution provided by the different proton plans for each patient. For instance, 
the individual OED values for thyroid (with RBE1.1) ranged from ≈ 2.0 to 19.2 
Gy(RBE) for patient 10 (12-year-old male) and ≈ 0.9 to 14.9 Gy(RBE) for patient 8 (8-
year-old male). For the EAR, the risk estimates are expected to increase with higher 
attained age and lower age at exposure. The EAR was higher for the female patients 
with the higher attained age, but this can also be attributed to the sex-specific higher 
risk for females. The EAR results did not verify any relationship between increase in 
risk with lower age at exposure, most likely due to the influence of dose distributions 
on the results as with the LAR estimates. Thus, the individual dose distributions seem 
to have a higher impact on risk estimates than the age at exposure for this patient group, 
due to the small age span of 5-12 years. Because of the magnitude in difference between 
70 
 
boys and girls, the sex-specific risk ratios are less sensitive to the inter-patient 
variations in dose distributions. 
There are presently no published studies that have calculated secondary cancer risk 
following proton therapy with inclusion of possible variations in the proton RBE. Thus, 
the results from this thesis can only be compared to studies that have estimated 
radiation-induced secondary cancer risks for proton therapy with a generic RBE of 1.1. 
Three studies estimating lifetime risk of lung and thyroid cancer using IMPT plans for 
proton CSI of medulloblastoma patients were found for comparison: Miralbell et al. 
(2002) [24], Mu et al. (2005) [25] and Stokkevåg et al. (2014) [29]. The results are 
presented in Table D.1 in Appendix D in comparison with the median risk estimates 
(including range) from this thesis. The adjusted risk estimates of these three studies all 
fall within the range of the risk estimates of this thesis, despite the median risk estimates 
being generally higher compared to all the adjusted risks from these studies. The lowest 
risk estimate was by Mu et al., but as this study only focussed on spinal irradiation this 
could potentially cause a lower risk estimates than studies that also include irradiation 
of the cranium. The patient cohorts were also smaller for these studies compared to the 
patient cohort of this thesis, with 1, 5 and 6 patients in Miralbell et al., Mu et al. and 
Stokkevåg et al., respectively. Also, only Stokkevåg et al. included risk estimates based 
on non-linear dose-response relationships that could be used for comparison, but the 
average organ risks were weighted according to the higher frequency of 
medulloblastoma in boys compared to girls, which could be a reason for the small 
deviation between these results and the results of this thesis.  
Several studies have compared secondary cancer risk estimates for proton therapy and 
photon therapy for paediatric medulloblastoma patients receiving CSI [24-31]. All 
these studies have shown lower risk predictions for all studied cancer sites following 
proton therapy compared to photon therapy, independent of dose-response relationship 
and risk model applied. Although these studies did not necessarily use the exact dose-
response relationships chosen for this thesis and also based their risk estimations on the 
clinical RBE of 1.1 only, it is still interesting to investigate whether the relative increase 
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in predicted risks with variable RBE seen in this thesis would change the preference of 
proton therapy over photon therapy in either of these studies. The risk estimates in each 
of these studies are presented in Table D.2 and Table D.3 in Appendix D. Overall, none 
of the risk estimates adjusted with the variable RBE model risk increase exceeded the 
estimated risks for photon therapy. This indicates that the variations that can be found 
in the proton RBE might not be large enough to prevent proton therapy plans from 
being the better option compared to photon therapy plans for paediatric 
medulloblastoma patients, at least for estimated risks of radiation-induced lung and 
thyroid cancer. The adjusted ratios of proton risk estimates over photon risk estimates 
were still very low for secondary thyroid cancer, where the ratios ranged from 0.03 to 
0.16. However, the adjusted ratios of secondary lung cancer risk estimates were much 
higher, approaching 1 in the case of Mu et al. (2005), Zhang et al. (2004), and Taddei 
et al. (2018) with risk ratios of 0.96, 0.98 and 0.95 (including secondary neutrons), 
respectively.  
Uncertainties and limitations 
The use of absolute risk estimations has been associated with very large uncertainties 
[18, 94, 95]. The BEIR VII report considers the uncertainties in the parameters 
estimated based on the LSS cohort data, the uncertainties that comes with applying this 
data to another population, and the uncertainty in the DDREF value to be of highest 
importance [18]. For the EAR estimates, the uncertainty lies mainly in the initial slope 
parameter β [77]. The uncertainties of relevance (which excludes the uncertainty in the 
DDREF) are displayed in the confidence intervals for each risk estimate in the tables 
of Appendix A, Appendix Band Appendix C. In addition, a major contributor to the 
uncertainty in the results of this thesis is the shape of the dose-response relationship for 
each organ at risk [96]. When it comes to the shape of the dose-response relationship, 
there is a clear increase in risk estimates for the linear dose-response relationship 
compared to the non-linear dose-response relationships. Using the linear dose-response 
relationship could thus lead to an overestimation of secondary cancer risk for higher 
dose ranges. On the other hand, the lower risk estimates provided by the non-linear 
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dose-response relationships may be an underestimation, and there also exists several 
additional uncertainties with the non-linear dose-response relationships used in this 
thesis. Both the linear-exponential and the plateau dose-response relationship described 
by Schneider et al. (2005) [76, 79] are derived from the same epidemiological data on 
patients receiving radiotherapy for Hodgkin’s disease and the EAR dose-response 
relationships, although based on another patient cohort, are also derived from 
Hodgkin’s patient data [77]. This could make it difficult to transfer these risk estimates 
to patients treated with radiotherapy for other malignancies, in this case 
medulloblastoma. Also, it has been pointed out that the dose reconstruction from the 
Hodgkin’s patients treated decades ago suffers from inaccuracy [76]. Lastly, there have 
only been a few indications and no clear definition of dose-response supporting these 
relationships in radiation epidemiology literature to date which leads to the possibility 
that these dose-response relationships are incorrect to use for secondary cancer risk 
estimations. The present inability to provide reasonable dose-response relationships for 
proton therapy therefore causes limitations in using the OED concept to account for 
inhomogeneous dose distributions associated with this modality [13, 17]. The 
indications to a possible shape of the dose-response relationship in literature have been 
regarding the evidence of a linear-exponential, or bell-shaped, dose-response 
relationship for thyroid cancer induction [97] and of a linear dose-response relationship 
for lung cancer [98]. Thus, there is a possibility that the risks predicted by the linear-
exponential dose-response model for secondary thyroid cancer induction are likely, and 
that there could be incentive for a linear dose-response relationship for secondary lung 
cancer, perhaps given a less steep slope than the one used in this thesis.  
It should also be emphasised that these dose-response relationships are theoretical, 
proposed to account for the biological effects in cells induced by ionising radiation, 
which the linear dose-response relationship does not consider, and there may be 
evidence supporting either of these dose-response relationships in future 
epidemiological studies. For this reason, theoretical dose-response relationships are 
viewed as complimentary to epidemiological studies by exploring aspects that can 
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affect the risk of secondary cancer incidence [17]. In any case, several studies have 
demonstrated that by using relative risk estimates the effect of the uncertainty in both 
shape of dose-response relationship as well as the interpatient variations in absorbed 
dose can be minimised [96, 99]. Therefore, the results in this thesis regarding the ratios 
and risk estimates relative to each other could be seen as more robust than the actual 
values of each risk estimate. 
Another factor of uncertainty is provided by the estimation of the proton RBE value. 
The alternative estimation of proton RBE values to the clinical value of 1.1 provided 
by the variable RBE models used in this thesis all exhibit uncertainties in how RBE 
varies with factors like LET, tissue type, endpoint and dose. Thus, the uncertainties in 
the estimation of a variable proton RBE will propagate into the dose-response models 
used to estimate secondary cancer risks following proton therapy. In a recent review, 
it was also pointed out that risk estimates in proton therapy (and heavy ion therapy) 
based solely on RBE for the endpoint of cell kill may be oversimplified [55].  
The results in this thesis are also experiencing limitations regarding factors that have 
not been taken into consideration in the process of calculating the predicted risks. One 
of these factors is the additional dose contribution from secondary scattered neutrons. 
As mentioned in chapter 2.3, these secondary particles are present to a certain but not 
completely ascertained degree during proton therapy beam delivery. There are 
presently no reliable methods able to account for the secondary neutron dose in proton 
therapy that comes from scattered neutrons either leaking from the treatment apparatus 
or produced inside the patient [37]. Although the severity of secondary neutron dose in 
proton therapy is not yet determined, it may provide an additional increase in risk of 
secondary cancer incidence for proton therapy. Studies have simulated this additional 
secondary neutron dose in literature to examine whether there would be a significant 
impact on secondary cancer risk estimations [25, 26, 30, 31, 68]. The results showed 
an increase in overall dose from proton therapy modalities, and thus in the risk 
estimations. However, the magnitude of the increase in dose was not large enough to 
result in risk estimations that caused a preference of photon therapy modalities over 
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those of proton therapy, even when using a radiation weighting factor for neutrons up 
to five times higher than recommended by the ICRP [68]. Another factor that might 
increase the risk of radiation-induced secondary cancer is the dose that comes from 
diagnostic imaging with ionising radiation. This risk in comparison to the one from the 
radiotherapy is however considered to be quite small and might not give much of an 
increase in the risk estimates in this thesis, and as such risks most likely will not be 
additive to the risk estimates from the radiation treatment, they would be difficult to 
study independently [11]. Lifestyle and genetics will also play a role in possibly 
increasing the risk estimates in this thesis, which are difficult to quantify in order to 




As paediatric medulloblastoma patients are at a particularly high risk of developing 
radiation-induced secondary cancers after treatment, the objective of this thesis was to 
investigate possible changes in risk estimations following use of variable RBE models 
compared to constant RBE for proton therapy. Of all the RBE models in this thesis, the 
RBE1.1 displayed the lowest risk estimates for all dose-response relationships and 
secondary cancer risk models employed. The risk will therefore increase compared to 
previous estimates when the proton RBE deviates from 1.1, with the size of this 
increase being dependent on variable RBE models employed. The relative increase in 
risk estimates with the variable RBE models was fairly insensitive to the choice of 
dose-response relationship, and also to the inter-patient variations in dose, which are 
both factors that influenced the absolute risk estimates greatly. By applying these 
relative increases in risk to estimations made for paediatric medulloblastoma patients 
following proton therapy with RBE1.1 in comparison with photon therapy made by 
other studies, the overall increase in risk estimates did overtake the values estimated 
for photon therapy. This indicates that proton CSI is the better treatment option for 
these patients with respect to secondary cancer risk estimates, regardless of a 
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Tables for LAR of radiation-induced secondary lung cancer. 
 
Table A.1: Lung risk coefficient l expressed in units of %/Gy per person with a 95% confidence 
interval (in parenthesis), calculated based on LAR table values (given as LAR per 100 000 
persons per 0.1 Gy) and procedures from the BEIR VII report. 
Patient index 1 2 3 4 5 6 7 8 9 10 
Sex Female Female Female Female Female Male Male Male Male Male 
Age at exposure 5 6 7 8 9 8 8 8 11 12 
LAR table value 608.0 587.2 566.4 545.6 524.8 234.0 234.0 234.0 208.8 201.6 



































Table A.2: OED for the lungs (in Gy(RBE)) for each patient, using the different RBE models 
and dose-response relationships. The lowest values are highlighted in blue and the highest 
values are highlighted in red. 
Patient 
index 
RBE1.1 LWD MCN2Gy MCN10Gy RØR2Gy RØR10Gy WIL 
Linear 
1 4.77 4.97 5.99 4.85 5.85 4.82 5.93 
2 3.77 4.01 4.96 3.89 4.81 3.86 4.95 
3 4.33 4.57 5.52 4.44 5.37 4.40 5.51 
4 4.83 5.16 6.32 5.00 6.13 4.95 6.34 
5 3.34 3.57 4.39 3.46 4.26 3.43 4.40 
6 4.83 5.14 6.27 4.99 6.09 4.94 6.29 
7 2.65 2.79 3.41 2.71 3.32 2.69 3.38 
8 4.61 4.86 5.89 4.73 5.74 4.69 5.87 
9 2.17 2.25 2.76 2.20 2.71 2.19 2.71 
10 3.17 3.38 4.22 3.28 4.10 3.25 4.22 
Linear-exponential 
1 1.25 1.26 1.37 1.27 1.37 1.27 1.35 
2 1.06 1.09 1.21 1.09 1.21 1.09 1.19 




4 1.25 1.26 1.36 1.27 1.37 1.27 1.34 
5 0.89 0.90 0.98 0.90 0.98 0.90 0.96 
6 1.22 1.22 1.30 1.23 1.31 1.23 1.28 
7 0.76 0.78 0.87 0.78 0.87 0.78 0.86 
8 1.20 1.21 1.32 1.22 1.33 1.22 1.30 
9 0.77 0.78 0.89 0.78 0.89 0.78 0.86 
10 0.99 1.01 1.13 1.01 1.13 1.01 1.11 
Plateau 
1 2.29 2.34 2.66 2.32 2.64 2.32 2.63 
2 1.87 1.95 2.27 1.92 2.24 1.91 2.25 
3 2.00 2.06 2.34 2.04 2.32 2.03 2.32 
4 2.31 2.39 2.74 2.36 2.71 2.35 2.72 
5 1.62 1.68 1.93 1.66 1.91 1.65 1.92 
6 2.29 2.36 2.68 2.33 2.65 2.33 2.66 
7 1.32 1.36 1.58 1.35 1.57 1.34 1.56 
8 2.20 2.27 2.58 2.24 2.56 2.23 2.56 











Table A.3: LAR of secondary lung cancer (in %) for each patient, using the different RBE 
models and dose-response relationships. The values in parenthesis are the 95% confidence 


























































































































































































































































































































































































































































Table A.4: The median LAR values (in %) of radiation-induced secondary lung cancer for the 
whole patient cohort with respects to each RBE model and each dose-response relationship 
with the range (min and max LAR value) in parenthesis.  
RBE model Dose-response relationship 
 Linear Linear-exponential Plateau 
RBE1.1 21.62 (6.80, 43.50) 5.64 (2.40, 11.38) 10.40 (3.77, 20.85) 
LWD 23.07 (7.05, 45.34) 5.68 (2.44, 11.52) 10.76 (3.85, 21.38) 
MCN2Gy 28.26 (8.64, 54.66) 6.16 (2.77, 12.47) 12.29 (4.50, 24.29) 
MCN10Gy 22.36 (6.90, 44.24) 5.71 (2.43, 11.54) 10.63 (3.81, 21.17) 
RØR2Gy 27.43 (8.49, 53.34) 6.18 (2.78, 12.52) 12.16 (4.48, 24.09) 
RØR10Gy 22.15 (6.86, 43.92) 5.71 (2.43, 11.55) 10.59 (3.80, 21.11) 








Table A.5: Median increase in LAR of secondary lung cancer with the variable RBE models 
relative to RBE1.1 with the range (min and max relative increase in LAR) in parenthesis. 
RBE model Dose-response relationship 
 Linear Linear-exponential Plateau 
LWD 1.06 (1.04, 1.07) 1.01 (1.00, 1.02) 1.03 (1.02, 1.04) 
MCN2Gy 1.30 (1.26, 1.33) 1.10 (1.07, 1.15) 1.19 (1.16, 1.22) 
MCN10Gy 1.03 (1.01, 1.04) 1.01 (1.01, 1.02) 1.02 (1.01, 1.03) 
RØR2Gy 1.26 (1.23, 1.30) 1.10 (1.07, 1.16) 1.18 (1.16, 1.21) 
RØR10Gy 1.02 (1.01, 1.03) 1.01 (1.01, 1.02) 1.02 (1.01, 1.02) 






Tables for LAR of radiation-induced secondary thyroid cancer. 
 
Table B.1: Thyroid risk coefficient r expressed in units of %/Gy per person with a 95% 
confidence interval (in parenthesis), calculated based on LAR table values (given as LAR per 
100 000 persons per 0.1 Gy) and procedures from the BEIR VII report.  
Patient index 1 2 3 4 5 6 7 8 9 10 
Sex Female Female Female Female Female Male Male Male Male Male 
Age at exposure 5 6 7 8 9 8 8 8 11 12 
LAR table value 419.0 390.2 361.4 332.6 303.8 60.40 60.40 60.40 46.60 43.20 



































Table B.2: OED for the thyroid (in [Gy(RBE)]) for each patient, using the different RBE models 
and dose-response relationships. The lowest values are highlighted in blue and the highest 
values are highlighted in red. 
Patient 
index 
RBE1.1 LWD MCN2Gy MCN10Gy RØR2Gy RØR10Gy WIL 
Linear 
1 4.56 5.00 6.58 4.83 6.39 4.78 6.63 
2 8.44 9.07 11.26 8.78 10.94 8.70 11.37 
3 1.24 1.40 1.99 1.35 1.92 1.33 1.99 
4 2.00 2.20 3.05 2.13 2.97 2.11 3.04 
5 6.08 6.60 8.45 6.39 8.19 6.33 8.53 
6 1.24 1.43 2.17 1.38 2.08 1.36 2.18 
7 5.81 6.25 7.94 6.06 7.73 6.01 7.96 
8 3.24 3.51 4.79 3.42 4.68 3.39 4.75 
9 3.30 3.62 4.95 3.51 4.81 3.48 4.95 
10 6.53 6.99 8.82 6.79 8.58 6.73 8.84 
Linear-exponential 
1 3.62 3.86 4.80 3.78 4.71 3.75 4.78 
2 6.06 6.34 7.32 6.22 7.22 6.19 7.33 




4 1.73 1.86 2.47 1.82 2.42 1.81 2.43 
5 4.57 4.84 5.81 4.74 5.70 4.71 5.81 
6 1.12 1.27 1.84 1.23 1.77 1.21 1.83 
7 4.43 4.65 5.57 4.56 5.49 4.54 5.53 
8 2.83 3.01 3.92 2.95 3.85 2.93 3.87 
9 2.80 3.01 3.91 2.94 3.83 2.92 3.88 
10 4.97 5.19 6.14 5.10 6.05 5.07 6.11 
Plateau 
1 1.26 1.28 1.35 1.27 1.35 1.27 1.35 
2 1.42 1.43 1.44 1.42 1.44 1.42 1.44 
3 0.61 0.64 0.80 0.63 0.79 0.63 0.78 
4 0.87 0.90 1.04 0.89 1.03 0.89 1.02 
5 1.31 1.33 1.38 1.32 1.38 1.32 1.38 
6 0.63 0.67 0.84 0.66 0.83 0.66 0.83 
7 1.34 1.35 1.40 1.35 1.40 1.35 1.39 
8 1.21 1.24 1.33 1.23 1.33 1.23 1.32 










Table B.3: Lifetime attributable risk of secondary thyroid cancer (in %) for each patient, using 
the different RBE models and dose-response relationships. The values in parenthesis are the 
95% confidence interval. The lowest LAR values are highlighted in blue and the highest 
values are highlighted in red. 
Patient 
index 





















































































































































































































































































































































































































































Table B.4: The median LAR values (in %) of radiation-induced secondary thyroid cancer for 
the whole patient cohort with respects to each RBE model and each dose-response 
relationship with the range (min and max LAR value) in parenthesis. 
RBE model Dose-response relationship 
 Linear Linear-exponential Plateau 
RBE1.1 6.00 (1.12, 49.39) 4.92 (1.01, 35.47) 2.25 (0.57, 8.33) 
LWD 6.61 (1.29, 53.09) 5.29 (1.15, 37.11) 2.34 (0.61, 8.35) 
MCN2Gy 8.99 (1.97, 65.93) 6.91 (1.67, 42.86) 2.80 (0.76, 8.51) 
MCN10Gy 6.40 (1.25, 51.41) 5.17 (1.11, 36.41) 2.32 (0.60, 8.34) 
RØR2Gy 8.72 (1.88, 64.04) 6.77 (1.61, 42.23) 2.77 (0.75, 8.50) 
RØR10Gy 6.33 (1.23, 50.95) 5.14 (1.10, 36.21) 2.31 (0.59, 8.34) 








Table B.5: Median increase in LAR of secondary thyroid cancer with the variable RBE models 
relative to RBE1.1 with the range (min and max relative increase in LAR) in parenthesis. 
RBE model Dose-response relationship 
 Linear Linear-exponential Plateau 
LWD 1.10 (1.07, 1.15) 1.07 (1.05, 1.13) 1.02 (1.00, 1.07) 
MCN2Gy 1.46 (1.33, 1.76) 1.36 (1.21, 1.65) 1.09 (1.01, 1.35) 
MCN10Gy 1.06 (1.04, 1.12) 1.04 (1.03, 1.10) 1.01 (1.00, 1.05) 
RØR2Gy 1.42 (1.30, 1.68) 1.33 (1.19, 1.59) 1.08 (1.01, 1.32) 
RØR10Gy 1.05 (1.03, 1.10) 1.04 (1.02, 1.09) 1.01 (1.00, 1.05) 






Tables for EAR of radiation-induced secondary lung cancer. 
 
Table C.1: Risk coefficient for radiation-induced lung cancer expressed in units of (10000 PY 
Gy)-1 including a 90% confidence interval (in parenthesis), calculated with equation (5.4), 
based on patient data and table values from Table 5.3. 
Patient index 1 2 3 4 5 6 7 8 9 10 
Sex Female Female Female Female Female Male Male Male Male Male 
Age at exposure 
(agex) 
5 6 7 8 9 8 8 8 11 12 




































Table C.2: OED for the lungs (in Gy(RBE)) for each patient, using the different RBE models 
and dose-response relationships. The lowest values are highlighted in blue and the highest 
values are highlighted in red. 
Patient 
index 
RBE1.1 LWD MCN2Gy MCN10Gy RØR2Gy RØR10Gy WIL 
Linear 
1 4.77 4.97 5.99 4.85 5.85 4.82 5.93 
2 3.77 4.01 4.96 3.89 4.81 3.86 4.95 
3 4.33 4.57 5.52 4.44 5.37 4.40 5.51 
4 4.83 5.16 6.32 5.00 6.13 4.95 6.34 
5 3.34 3.57 4.39 3.46 4.26 3.43 4.40 
6 4.83 5.14 6.27 4.99 6.09 4.94 6.29 
7 2.65 2.79 3.41 2.71 3.32 2.69 3.38 
8 4.61 4.86 5.89 4.73 5.74 4.69 5.87 
9 2.17 2.25 2.76 2.20 2.71 2.19 2.71 
10 3.17 3.38 4.22 3.28 4.10 3.25 4.22 
Bell-shaped 
1 3.22 3.31 3.77 3.27 3.74 3.26 3.73 
2 2.61 2.72 3.18 2.68 3.14 2.67 3.16 




4 3.27 3.40 3.90 3.35 3.86 3.34 3.88 
5 2.29 2.39 2.75 2.35 2.72 2.34 2.73 
6 3.26 3.38 3.84 3.33 3.80 3.32 3.82 
7 1.83 1.89 2.19 1.87 2.17 1.86 2.17 
8 3.10 3.20 3.65 3.16 3.62 3.15 3.62 
9 1.61 1.65 1.93 1.63 1.92 1.62 1.89 
10 2.28 2.39 2.82 2.35 2.78 2.34 2.80 
Plateau 
1 3.07 3.15 3.60 3.12 3.57 3.11 3.56 
2 2.49 2.60 3.04 2.56 3.00 2.55 3.02 
3 2.71 2.80 3.18 2.76 3.15 2.75 3.15 
4 3.11 3.23 3.72 3.19 3.68 3.17 3.70 
5 2.18 2.27 2.62 2.24 2.59 2.23 2.61 
6 3.10 3.21 3.66 3.17 3.62 3.15 3.64 
7 1.75 1.81 2.10 1.78 2.08 1.78 2.07 
8 2.96 3.05 3.49 3.01 3.46 3.00 3.46 




10 2.18 2.28 2.70 2.24 2.66 2.23 2.68 
Full model 
1 2.98 3.06 3.52 3.02 3.48 3.01 3.48 
2 2.41 2.52 2.97 2.48 2.92 2.47 2.95 
3 2.64 2.73 3.12 2.69 3.08 2.68 3.09 
4 3.02 3.14 3.64 3.09 3.59 3.08 3.62 
5 2.11 2.20 2.56 2.17 2.52 2.16 2.55 
6 3.00 3.12 3.58 3.07 3.54 3.06 3.56 
7 1.70 1.76 2.05 1.73 2.03 1.72 2.03 
8 2.87 2.97 3.42 2.92 3.38 2.91 3.38 
9 1.49 1.53 1.80 1.51 1.79 1.51 1.77 







Table C.3: Excess absolute risk of secondary lung cancer (per 10000 PY) for each patient, 
using the different RBE models and dose-response relationships. The values in parenthesis 
are the 90% confidence interval. The lowest EAR values are highlighted in blue and the 
highest values are highlighted in red. 
Patient 
index 

































































































































































































































































































































































































































































































































































































Table C.4: The median EAR values (per 10000 PY) of radiation-induced secondary lung 
cancer for the whole patient cohort with respects to each RBE model and each dose-response 
relationship with the range (min and max EAR value) in parenthesis. 
RBE model Dose-response relationship 
 Linear Bell-shaped Plateau Full model 
RBE1.1 61.49 (24.77, 98.44) 41.90 (18.36, 66.69) 39.84 (17.59, 63.45) 38.59 (17.03, 61.52) 
LWD 65.61 (25.69, 105.15) 43.51 (18.79, 69.30) 41.39 (18.00, 65.97) 40.19 (17.45, 64.12) 
MCN2Gy 80.34 (31.46, 128.84) 49.87 (22.03, 79.56) 47.56 (21.13, 75.96) 46.47 (20.56, 74.26) 
MCN10Gy 63.59 (25.12, 101.88) 42.91 (18.56, 68.35) 40.80 (17.79, 65.03) 39.56 (17.23, 63.11) 
RØR2Gy 77.98 (30.90, 125.03) 49.33 (21.91, 78.71) 47.00 (21.01, 75.05) 45.84 (20.42, 73.25) 
RØR10Gy 63.00 (25.00, 100.93) 42.72 (18.53, 68.06) 40.63 (17.76, 64.75) 39.37 (17.19, 62.81) 








Table C.5: Median increase in EAR of secondary lung cancer with the variable RBE models 
relative to RBE1.1 with the range (min and max relative increase in EAR) in parenthesis. 
RBE model Dose-response relationship 
 Linear Bell-shaped Plateau Full model 
LWD 1.06 (1.04, 1.07) 1.04 (1.02, 1.05) 1.04 (1.02, 1.04) 1.04 (1.02, 1.05) 
MCN2Gy 1.30 (1.26, 1.33) 1.20 (1.17, 1.24) 1.20 (1.17, 1.24) 1.21 (1.18, 1.24) 
MCN10Gy 1.03 (1.01, 1.04) 1.02 (1.01, 1.03) 1.02 (1.01, 1.03) 1.02 (1.01, 1.03) 
RØR2Gy 1.26 (1.23, 1.30) 1.18 (1.16, 1.22) 1.19 (1.16, 1.22) 1.20 (1.17, 1.23) 
RØR10Gy 1.02 (1.01, 1.03) 1.02 (1.01, 1.02) 1.02 (1.01, 1.02) 1.02 (1.01, 1.02) 







Comparison of results from this thesis with that of other studies, and adjustment of 
results from other studies with the highest median relative risk estimates by variable 
RBE models in this thesis. 
Comparison of results (Table D.1): In the study by Mu et al., the lifetime risk of lung 
and thyroid cancer was not estimated individually but could be recreated using the 
method described in the article with the organ absorbed doses listed. As the dose to the 
thyroid was 0 Gy(RBE) in both Miralbell et al. and Mu et al., the calculations could 
only be done for the lungs. These two studies only used a linear model to estimate risks 
for 1 and 5 paediatric medulloblastoma patients, respectively, while Stokkevåg et al. 
used a linear, linear-exponential and plateau model to estimate risks for 6 paediatric 
medulloblastoma patients. All studies used a DDREF in their estimations, which was 
removed for the comparison (2 from the ICRP 60 recommendations for Miralbell et al. 
and Mu et al., and 1.5 from the BEIR VII recommendations for Stokkevåg et al.). The 
dose of 36 Gy(RBE) used in Miralbell et al. was adjusted to a 23.4 Gy(RBE) regime as 
well as using the median lifetime of this study (92 years) with their calculated risk in 
yearly rate (in %) to yield lifetime risk. The tissue weighting factor for lungs of 0.12 









Table D.1: Comparison of lifetime risk of radiation-induced secondary cancer following proton 
CSI with pencil beam scanning from different studies. The lifetime risks from the chosen 
studies have been modified to be comparable with the results in this thesis. 
Study Dose-response relationship 
 Linear Linear-exponential Plateau 
 Lung Thyroid Lung Thyroid Lung Thyroid 
Miralbell et al. (2002) 10.0 - - - - - 
Mu et al. (2005) 9.9 - - - - - 





















Table D.2 and D.3: Results from several studies that have compared secondary cancer 
risk estimates for proton therapy and photon therapy for paediatric medulloblastoma 
patients receiving CSI [24-31]. The risk estimates in each of these studies presented in 
Table D.2 are adjusted by the highest median relative risk made by the variable RBE 
models in this thesis. The corresponding resulting risk relative to the photon risk 





Table D.2: Lifetime risk of radiation-induced secondary cancer values in [%] for proton therapy 
from different studies comparing photon and proton risk estimations. Each value is adjusted 
by the highest median relative risks found in this thesis, corresponding to the dose-response 











Miralbell et al. (2002)a Linear, IMPT 0.01 0.013 - - 
Mu et al. (2005)b 
Linear, IMPT (incl. 
neutrons) 
4.9 6.4 - - 
Newhauser et al. (2009)a 
Linear, IMPT 0.011 0.014 0.004 0.006 
Linear, PS 0.014 0.018 0.005 0.007 
Zhang et al. (2013)c Linear, PS 11.4 14.8 0.5 0.7 
Zhang et al. (2014)d 
Linear, PS median 
(range) 
12.0 (4.0, 36.0) 15.6 (5.2, 46.8) 1.0 (0.2, 4.0) 1.5 (0.3, 5.9) 
Stokkevåg et al. (2014)e 
Linear, IMPT (PS) 10.0 (7.8) 13.0 (10.1) 1.0 (0.8) 1.5 (1.2) 
Lin-exp, IMPT 
(PS) 
2.0 (1.0) 2.2 (1.1) 0.8 (0.9) 1.1 (1.2) 
Plateau, IMPT (PS) 4.0 (2.2) 4.8 (2.6) 0.6 (1.0) 0.7 (1.1) 
Taddei et al. (2015)c 
Linear, PS (incl. 
neutrons) 
12.3 (16.8) 16.0 (21.8) 1.5 (3.9) 2.2 (5.7) 
Taddei et al. (2018)c 
Linear, PS (incl. 
neutrons) 
11.7 (13.0) 15.2 (16.9) 1.5 (2.4) 2.2 (3.5) 
a Photon risk estimates were done for either CRT or IMRT or both – for both, ratio is listed as CRT/IMRT 
a Risk given in yearly rate [%], thus given more decimals to show change with variable RBE 
b Estimated organ-specific lifetime risk from article information (average organ dose in table II) and the ICRP 103 report (table A.4.2) 
c Estimated organ-specific LAR from article information and the BEIR VII report (table 12D-1) 
d Calculated median LAR from supplementary material to the article 




Table D.3: The ratio of adjusted proton risk estimates normalised to photon risk estimates are 
given for each organ. Photon risk estimates were done for either CRT or IMRT or both – for 










thyroid ratio  
Miralbell et al. (2002)a Linear, IMPT 0.14 0.19/0.19 - - 
Mu et al. (2005)b 
Linear, IMPT (incl. 
neutrons) 
0.91/0.42 0.96/0.44 - - 
Newhauser et al. (2009)a 
Linear, IMPT 0.16/0.16 0.20/0.20 0.02/0.07 0.03/0.10 
Linear, PS 0.20/0.20 0.26/0.26 0.03/0.08 0.04/0.12 
Zhang et al. (2013)c Linear, PS 0.63 0.82 0.04 0.05 
Zhang et al. (2014)d 
Linear, PS median 
(range) 
0.75 0.98 0.06 0.08 
Stokkevåg et al. (2014)e 
Linear, IMPT (PS) 0.56 (0.43) 0.72 (0.56) 0.03 (0.003) 0.05 (0.04) 
Lin-exp, IMPT (PS) 0.40 (0.20) 0.44 (0.22) 0.05 (0.01) 0.07 (0.08) 
Plateau, IMPT (PS) 0.48 (0.27) 0.58 (0.31) 0.09 (0.14) 0.10 (0.16) 
Taddei et al. (2015)c 
Linear, PS (incl. 
neutrons) 
0.32 (0.44) 0.42 (0.58) 0.03 (0.07) 0.04 (0.10) 
Taddei et al. (2018)c 
Linear, PS (incl. 
neutrons) 
0.66 (0.73) 0.86 (0.95) 0.04 (0.06) 0.06 (0.09) 
a Photon risk estimates were done for either CRT or IMRT or both – for both, ratio is listed as CRT/IMRT 
a Risk given in yearly rate [%], thus given more decimals to show change with variable RBE 
b Estimated organ-specific lifetime risk from article information (average organ dose in table II) and the ICRP 103 report (table A.4.2) 
c Estimated organ-specific LAR from article information and the BEIR VII report (table 12D-1) 
d Calculated median LAR from supplementary material to the article 
e Average LAR eye measured from Figure 6 in article 
 
 
